

International Nonproprietary Names for Pharmaceutical Substances (INN)

RECOMMENDED International Nonproprietary Names: List 72

Notice is hereby given that, in accordance with paragraph 7 of the Procedure for the Selection of Recommended International Nonproprietary Names for Pharmaceutical Substances [*Off. Rec. Wld Health Org.*, 1955, **60**, 3 (Resolution EB15.R7); 1969, **173**, 10 (Resolution EB43.R9); Resolution EB115.R4 (EB115/2005/REC/1)], the following names are selected as Recommended International Nonproprietary Names. The inclusion of a name in the lists of Recommended International Nonproprietary Names does not imply any recommendation of the use of the substance in medicine or pharmacy.

Lists of Proposed (1–109) and Recommended (1–70) International Nonproprietary Names can be found in *Cumulative List No. 15, 2013* (available in CD-ROM only).

Dénominations communes internationales des Substances pharmaceutiques (DCI)

Dénominations communes internationales RECOMMANDÉES: Liste 72

Il est notifié que, conformément aux dispositions du paragraphe 7 de la Procédure à suivre en vue du choix de Dénominations communes internationales recommandées pour les Substances pharmaceutiques [*Actes off. Org. mond. Santé*, 1955, **60**, 3 (résolution EB15.R7); 1969, **173**, 10 (résolution EB43.R9); résolution EB115.R4 (EB115/2005/REC/1)] les dénominations ci-dessous sont choisies par l'Organisation mondiale de la Santé en tant que dénominations communes internationales recommandées. L'inclusion d'une dénomination dans les listes de DCI recommandées n'implique aucune recommandation en vue de l'utilisation de la substance correspondante en médecine ou en pharmacie.

On trouvera d'autres listes de Dénominations communes internationales proposées (1–109) et recommandées (1–70) dans la *Liste récapitulative No. 15, 2013* (disponible sur CD-ROM seulement).

Denominaciones Comunes Internacionales para las Sustancias Farmacéuticas (DCI)

Denominaciones Comunes Internacionales RECOMENDADAS: Lista 72

De conformidad con lo que dispone el párrafo 7 del Procedimiento de Selección de Denominaciones Comunes Internacionales Recomendadas para las Sustancias Farmacéuticas [*Act. Of. Mund. Salud*, 1955, **60**, 3 (Resolución EB15.R7); 1969, **173**, 10 (Resolución EB43.R9); Resolución EB115.R4 (EB115/2005/REC/1) EB115.R4 (EB115/2005/REC/1)], se comunica por el presente anuncio que las denominaciones que a continuación se expresan han sido seleccionadas como Denominaciones Comunes Internacionales Recomendadas. La inclusión de una denominación en las listas de las Denominaciones Comunes Recomendadas no supone recomendación alguna en favor del empleo de la sustancia respectiva en medicina o en farmacia.

Las listas de Denominaciones Comunes Internacionales Propuestas (1–109) y Recomendadas (1–70) se encuentran reunidas en *Cumulative List No. 15, 2013* (disponible sólo en CD-ROM).

Latin, English, French, Spanish:
Recommended INN

Chemical name or description; Molecular formula; Graphic formula

DCI Recommandée

Nom chimique ou description; Formule brute; Formule développée

DCI Recomendada

Nombre químico o descripción; Fórmula molecular; Fórmula desarrollada

abametapirum

abametapir

5,5'-dimethyl-2,2'-bipyridinyl


abamétapir

5,5'-diméthyl-2,2'-bipyridinyle

abametapir

5,5'-dimetil-2,2'-bipiridinilo

$C_{12}H_{12}N_2$



acidum bempedoicum

bempedoic acid

8-hydroxy-2,2,14,14-tetramethylpentadecanedioic acid


acide bempédoïque

acide 8-hydroxy-2,2,14,14-tétraméthylpentadécanedioïque

ácido bempedoico

ácido 8-hidroxi-2,2,14,14-tetrametilpentadecanodióico

$C_{19}H_{36}O_5$



aclerastidum

aclerastide

[3-(L-2-aminohexanoic acid)]angiotensin II-(1-7)-peptide

aclérastide

[3-(acide L-2-aminohexanoïque)]angiotensine II-(1-7)-peptide

aclerastida

[3-(ácido L-2-aminohexanoico)]angiotensina II-(1-7)-péptido

$C_{42}H_{64}N_{12}O_{11}$

H-Asp—Arg—Nle—Tyr—Ile—His—Pro—OH



7

aducanumabum #

aducanumab


immunoglobulin G1-kappa, anti-[*Homo sapiens* amyloid beta (Aβeta, Aβ) peptide], *Homo sapiens* monoclonal antibody; gamma1 heavy chain (1-453) [*Homo sapiens* VH (IGHV3-33*01 (93.90%) -(IGHD)-IGHJ6*03) [8.8.17] (1-124) -IGHG1*03 (CH1 (125-222), hinge (223-237), CH2 (238-347), CH3 (348-452), CHS K2>del (453)) (125-453)], (227-214')-disulfide with kappa light chain (1'-214') [*Homo sapiens* V-KAPPA (IGKV1-39*01 (100.00%) -IGKJ4*01) [6.3.9] (1'-107') -IGKC*01 (108'-214')]; dimer (233-233":236-236")-bisdisulfide

aducanumab	immunoglobuline G1-kappa, anti-[<i>Homo sapiens</i> peptide amyloïde bêta (Abêta, Aβ)], <i>Homo sapiens</i> anticorps monoclonal; chaîne lourde gamma1 (1-453) [<i>Homo sapiens</i> VH (IGHV3-33*01 (93.90%) -(IGHD)-IGHJ6*03 [8.8.17] (1-124) -IGHG1*03 (CH1 (125-222), charnière (223-237), CH2 (238-347), CH3 (348-452), CHS K2>del (453)) (125-453)), (227-214')-disulfure avec la chaîne légère kappa (1'-214') [<i>Homo sapiens</i> V-KAPPA (IGKV1-39*01 (100.00%) -IGKJ4*01 [6.3.9] (1'-107') -IGKC*01 (108'-214'))]; dimère (233-233''-236-236'')-bisdisulfure
aducanumab	inmunoglobulina G1-kappa, anti-[péptido amiloide beta de <i>Homo sapiens</i> (Abeta, Aβ)], <i>Homo sapiens</i> anticuerpo monoclonal; cadena pesada gamma1 (1-453) [<i>Homo sapiens</i> VH (IGHV3-33*01 (93.90%) -(IGHD)-IGHJ6*03 [8.8.17] (1-124) -IGHG1*03 (CH1 (125-222), bisagra (223-237), CH2 (238-347), CH3 (348-452), CHS K2>del (453)) (125-453)), (227-214')-disulfuro con la cadena ligera kappa (1'-214') [<i>Homo sapiens</i> V-KAPPA (IGKV1-39*01 (100.00%) -IGKJ4*01 [6.3.9] (1'-107') -IGKC*01 (108'-214'))]; dímero (233-233''-236-236'')-bisdisulfuro
	Heavy chain / Chaîne lourde / Cadena pesada QVQLVESGGG VVQPGRSRLR SCAASGFAFS SYGMHWVRQA PGKGLEWVAV 50 IWFDGTTKKYY TDSVKGRFTI SRDNSKNTLY LQMNTLRAED TAVYYCARDR 100 GIGARRGPYY MDVWGKRTTV TVSSASTKGP SVFPLAPSSK STSGGTAALG 150 CLVKDYFPEP TVTSWNSGAL TSGVHTFPAV LQSSGLYSLS SVVTVPSSSL 200 GTQTYICNVN HKPSNTKVDK RVEPKSCDKT HTCPPCPAPE LLGGPSVFLF 250 PPKPKDTLMI SRTPEVTCVV VDVSHEDPEV KFNWYVDGVE VHNAKTKPRE 300 EQYNSTYRVV SVLTVLHQDW LNGKEYKCKV SNKALPAPIE KTISKAKGQP 350 REFQVYTLPP SREEMTKNQV SLTCLVKGFY PSDIAVEWES NGQPENNYKT 400 TPPVLDSDGS FFLYSKLTVD KSRWQQGNVF SCSVMHEALH NHYTQKSLSL 450 SPG 453 Light chain / Chaîne légère / Cadena ligera DIQMTQSPSS LSASVGRDVT ITCRASQSI SYLNWYQQKP GKAPKLLIYA 50 ASSLQSGVPS RFGSGSGSDT FTLTISSLQP EDFATYYCQQ SYSTPLTFGG 100 GTKVEIKRTV AAPSVFIFPP SDEQLKSGTA SVVCLLNNFY PREAKVQWKV 150 DNALQSGNSQ ESVTEQDSKD STYSLSSLT LSKADYEKKH VYACEVTHQG 200 LSPFVTKSFN RGEC 214 Disulfide bridges location / Position des ponts disulfure / Posiciones de los puentes disulfuro Intra-H (C23-C104) 22"-96 151"-207 268"-328 374"-432 22"-96" 151"-207" 268"-328" 374"-432" Intra-L (C23-C104) 23'-88" 134'-194" 23'''-88''' 134'''-194''' Inter-H-L (h 5-CL 126) 227-214' 227"-214" Inter-H-H (h 11, h 14) 233-233" 236-236" N-glycosylation sites / Sites de N-glycosylation / Posiciones de N-glicosilación H CH2 N84.4: 304, 304"
alpelisibum	
alpelisib	(2 <i>S</i>)- <i>N</i> ¹ -(4-methyl-5-[1-(1,1,1-trifluoro-2-methylpropan-2-yl)pyridin-4-yl]-1,3-thiazol-2-yl)pyrrolidine-1,2-dicarboxamide
alpelisib	(2 <i>S</i>)- <i>N</i> ¹ -(4-méthyl-5-[1-(1,1,1-trifluoro-2-méthylpropan-2-yl)pyridin-4-yl]-1,3-thiazol-2-yl)pyrrolidine-1,2-dicarboxamide
alpelisib	(2 <i>S</i>)- <i>N</i> ¹ -(4-metil-5-[1-(1,1,1-trifluoro-2-metilpropan-2-il)piridin-4-il]-1,3-tiazol-2-il)pirrolidina-1,2-dicarboxamida



andexanetum alfa # andexanet alfa	des-(6-39)-human blood-coagulation factor X light chain (98-108')-disulfide with [185'-alanine (S>A)]human activated factor Xa heavy chain, produced in Chinese hamster ovary (CHO) cells (glycoform alfa)
andexanet alfa	(98-108')-disulfure entre la dès-(6-39)-chaîne légère du facteur X de coagulation humain et la [185'-alanine (S>A)]chaîne lourde du facteur Xa activé de coagulation humain glycosylé, produit par les cellules ovariennes de hamster chinois (CHO) (glycoforme alfa)
andexanet alfa	(98-108')-disulfuro entre la des-(6-39)-cadena ligera del factor X de coagulación humano y la [185'-alanina (S>A)]cadena pesada del factor Xa activado de coagulación humano glicosilado, producido por cultivo de células ováricas de hamster chino (CHO) (glicoforma alfa)
Light chain / Chaîne légère / Cadena ligera	
ANSFLFWNKY KGDQCE TSP CQNQGKCK DG LGEYTCTCLE GFEGKNCELF 50	
TRKLC SL DNG DCDQFCHEEQ NS VVC SCARG Y TL ADNGKAC IPTG PY PCGK 100	
QT L ER 105	
Heavy chain / Chaîne lourde / Cadena pesada	
IVGGQECKDG ECPWQALLIN EENEGFCGGT ILSEFYILTA AHCLYQAKRF 50'	
KVRVGDRNTE QEEGGEAVHE VEVVIKHNRF TKETYDFDIA VLRKTPITF 100'	
RMNVAPACLP ERDWAESTLM TQKTGIVSGF GRTHEKGRQS TRLMLEVPY 150'	
VDRNSCKLSS SFIITQNMFC AGYDTKQEDA CQGDAGGPHV TRFKDTYFVT 200'	
GIVSWGEGCA RKGKYGIYTK VTAFLKWIDR SMKTRGLPKA KSHAPEVITS 250'	
SPLK 254'	
Disulfide bridges location / Position des ponts disulfure / Posiciones de los puentes disulfuro	
7'-12' 16-27 21-36 27'-43' 38-47 55-66	
62-75 77-90 98-108' 156'-170' 181'-209'	
Modified residue / Résidu modifié / Resto modificado	
D 29 (3R)-3-hydroxyAsp H NH₂ HO₂C CO₂H HO H	
Glycosylation sites (* confirmed) / Sites de glycosylation (* confirmé) / Posiciones de glicosilación (* confirmada)	
Ser-56 Ser-72 Ser-76 Thr-82 *Thr-249'	

apabetalonum apabetalone	2-[4-(2-hydroxyethoxy)-3,5-dimethylphenyl]-5,7-dimethoxyquinazolin-4(3H)-one
apabétalone	2-[4-(2-hydroxyéthoxy)-3,5-diméthylphényl]-5,7-diméthoxyquinazolin-4(3H)-one
apabetalona	2-[4-(2-hidroxiétoxi)-3,5-dimetilfenil]-5,7-dimetoxiquinazolin-4(3H)-ona

C₂₀H₂₂N₂O₅

apatorsenum
apatorsen


all-P-ambo-2'-O-(2-methoxyethyl)-P-thioguanlyl-(3'→5')-2'-O-(2-methoxyethyl)-P-thioguanlyl-(3'→5')-2'-O-(2-methoxyethyl)-P-thioadenyl-(3'→5')-2'-deoxy-5-methyl-P-thiocytidyl-(3'→5')-2'-deoxy-P-thioguanlyl-(3'→5')-2'-deoxy-5-methyl-P-thiocytidyl-(3'→5')-2'-deoxy-P-thioguanlyl-(3'→5')-2'-deoxy-P-thioguanlyl-(3'→5')-2'-deoxy-5-methyl-P-thiocytidyl-(3'→5')-2'-deoxy-5-methyl-P-thiocytidyl-(3'→5')-P-thiothymidyl-(3'→5')-2'-deoxy-5-methyl-P-thiocytidyl-(3'→5')-2'-deoxy-P-thioguanlyl-(3'→5')-2'-deoxy-P-thioguanlyl-(3'→5')-2'-O-(2-methoxyethyl)-5-methyl-P-thiouridyl-(3'→5')-2'-O-(2-methoxyethyl)-5-methyl-P-thiocytidyl-(3'→5')-2'-O-(2-methoxyethyl)-P-thioadenyl-(3'→5')-2'-O-(2-methoxyethyl)-5-methyluridine

apatorsen

tout-P-ambo-2'-O-(2-méthoxyéthyl)-P-thioguanlyl-(3'→5')-2'-O-(2-méthoxyéthyl)-P-thioguanlyl-(3'→5')-2'-O-(2-méthoxyéthyl)-P-thioadényl-(3'→5')-2'-déoxy-5-méthyl-P-thiocytidyl-(3'→5')-2'-déoxy-P-thioguanlyl-(3'→5')-2'-déoxy-5-méthyl-P-thiocytidyl-(3'→5')-2'-déoxy-P-thioguanlyl-(3'→5')-2'-déoxy-P-thioguanlyl-(3'→5')-2'-déoxy-5-méthyl-P-thiocytidyl-(3'→5')-2'-déoxy-5-méthyl-P-thiocytidyl-(3'→5')-P-thiothymidyl-(3'→5')-2'-déoxy-5-méthyl-P-thiocytidyl-(3'→5')-2'-déoxy-P-thioguanlyl-(3'→5')-2'-déoxy-P-thioguanlyl-(3'→5')-2'-O-(2-méthoxyéthyl)-5-méthyl-P-thiouridyl-(3'→5')-2'-O-(2-méthoxyéthyl)-5-méthyl-P-thiocytidyl-(3'→5')-2'-O-(2-méthoxyéthyl)-P-thioadényl-(3'→5')-2'-O-(2-méthoxyéthyl)-5-méthyluridine


apatorsén

todo-P-ambo-2'-O-(2-metoxietil)-P-tioguanilil-(3'→5')-2'-O-(2-metoxietil)-P-tioguanilil-(3'→5')-2'-O-(2-metoxietil)-P-tioguanilil-(3'→5')-2'-desoxi-5-metil-P-tiocitidilil-(3'→5')-2'-desoxi-P-tioguanilil-(3'→5')-2'-desoxi-5-metil-P-tiocitidilil-(3'→5')-2'-desoxi-P-tioguanilil-(3'→5')-2'-desoxi-5-metil-P-tiocitidilil-(3'→5')-2'-desoxi-P-tioguanilil-(3'→5')-2'-desoxi-5-metil-P-tiocitidilil-(3'→5')-P-tiotimidilil-(3'→5')-2'-desoxi-5-metil-P-tiocitidilil-(3'→5')-2'-desoxi-P-tioguanilil-(3'→5')-2'-desoxi-P-tioguanilil-(3'→5')-2'-O-(2-metoxietil)-5-metil-P-tiouridilil-(3'→5')-2'-O-(2-metoxietil)-5-metil-P-tiocitidilil-(3'→5')-2'-O-(2-metoxietil)-P-tioadenilil-(3'→5')-2'-O-(2-metoxietil)-5-metiluridina



(3'→5')d(*P*-thio)(rG-rG-rG-rA-mC-G-mC-G-G-mC-G-mC-T-mC-G-G-rU-rC-rA-rU)

Modified nucleosides / Nucleosides modifiés / Nucleosidos modificados



astodrimelum
astodrimer



N^2, N^6 -bis(N^2, N^6 -bis(N^2, N^6 -bis(N^2, N^6 -bis(N^2, N^6 -bis[(3,6-disulfonaphthalen-1-yloxy)acetyl]-L-lysyl)-L-lysyl)-L-lysyl)-L-lysyl)- N^1 -(diphenylmethyl)-L-lysineamide

astodrimère

N^2, N^6 -bis(N^2, N^6 -bis(N^2, N^6 -bis(N^2, N^6 -bis(N^2, N^6 -bis[(3,6-disulfonaphthalen-1-yloxy)acétyle]-L-lysyl)-L-lysyl)-L-lysyl)-L-lysyl)- N^1 -(diphénylméthyl)-L-lysineamide

astodrímero

N^2, N^6 -bis(N^2, N^6 -bis(N^2, N^6 -bis(N^2, N^6 -bis(N^2, N^6 -bis[(3,6-disulfonafthalen-1-iloxi)acetil]-L-lisil)-L-lisil)-L-lisil)-L-lisil)- N^1 -(difenilmetil)-L-lisinaida



batefenterolum

batefenterol


1-(3-[[2-chloro-4-(([(2*R*)-2-hydroxy-2-(8-hydroxy-2-oxo-1,2-dihydroquinolin-5-yl)ethyl]amino)methyl)-5-methoxyphenyl]amino]-3-oxopropyl)piperidin-4-yl (1,1-biphenyl-2-yl)carbamate

batéfentérol

(1,1-biphényl-2-yl)carbamate de 1-(3-[[2-chloro-4-(([(2*R*)-2-hydroxy-2-(8-hydroxy-2-oxo-1,2-dihydroquinolin-5-yl)éthyl]amino)méthyl)-5-méthoxyphényl]amino]-3-oxopropyl)pipéridin-4-yle

batefenterol

(1,1-bifenil-2-il)carbamato de 1-(3-[[2-cloro-4-(([(2*R*)-2-hidroxi-2-(8-hidroxi-2-oxo-1,2-dihidroquinolin-5-il)etil]amino)metil)-5-metoxifenil]amino]-3-oxopropil)piperidin-4-ilo

C₄₀H₄₂ClN₅O₇**bimekizumabum #**

bimekizumab

immunoglobulin G1-kappa, anti-[*Homo sapiens* IL17A (interleukin 17A) and *Homo sapiens* IL17F (interleukin 17F)], humanized monoclonal antibody;
gamma1 heavy chain (1-455) [humanized VH (*Homo sapiens* IGHV3-7*01 (88.70%) -(IGHD)-IGHJ1*01) [8.8.18] (1-125) -*Homo sapiens* IGHG1*01 (CH1 (126-223), hinge (224-238), CH2 (239-348), CH3 (349-453), CHS (454-455)) (126-455)], (228-214')-disulfide with kappa light chain (1'-214') [humanized V-KAPPA (*Homo sapiens* IGKV1-13*02 (80.00%) -IGKJ1*01) [6.3.9] (1'-107') -*Homo sapiens* IGKC*01 (108'-214')]; dimer (234-234":237-237")-bisdisulfide

bimékizumab

immunoglobuline G1-kappa, anti-[*Homo sapiens* IL17A (interleukine 17A) et *Homo sapiens* IL17F (interleukine 17F)], anticorps monoclonal humanisé;
chaîne lourde gamma1 (1-455) [VH humanisé (*Homo sapiens* IGHV3-7*01 (88.70%) -(IGHD)-IGHJ1*01) [8.8.18] (1-125) -*Homo sapiens* IGHG1*01 (CH1 (126-223), charnière (224-238), CH2 (239-348), CH3 (349-453), CHS (454-455)) (126-455)], (228-214')-disulfure avec la chaîne légère kappa (1'-214') [V-KAPPA humanisé (*Homo sapiens* IGKV1-13*02 (80.00%) -IGKJ1*01) [6.3.9] (1'-107') -*Homo sapiens* IGKC*01 (108'-214')]; dimère (234-234":237-237")-bisdisulfure

bimekizumab

immunoglobulina G1-kappa, anti-[*Homo sapiens* IL17A (interleukina 17A) et *Homo sapiens* IL17F (interleukina 17F)], anticuerpo monoclonal humanizado;
cadena pesada gamma1 (1-455) [VH humanizado (*Homo sapiens* IGHV3-7*01 (88.70%) -(IGHD)-IGHJ1*01) [8.8.18] (1-125) -*Homo sapiens* IGHG1*01 (CH1 (126-223), bisagra (224-238), CH2 (239-348), CH3 (349-453), CHS (454-455)) (126-455)], (228-214')-disulfuro con la cadena ligera kappa (1'-214') [V-KAPPA humanizado (*Homo sapiens* IGKV1-13*02 (80.00%) -IGKJ1*01) [6.3.9] (1'-107') -*Homo sapiens* IGKC*01 (108'-214')]; dímero (234-234":237-237")-bisdisulfuro

Heavy chain / Chaîne lourde / Cadena pesada

EVQLVESGGG	LVQPGGSLRL	SCAASGFTFS	DYNMAWVRQA	PGKGLEWVAT	50
ITYEGRNTYY	RDSVKGRFTI	SRDNAKNSLY	LQMNSLRAED	TAVYYCASPP	100
QYYEGSIYRL	WFAHWGQGT	VTVSSASTKG	PSVFPLAPSS	KSTSGGTAAL	150
GCLVKDYFPE	PVTVSWNSGA	LTSGVHTFPA	VLQSSGLYSL	SSVVTVPSSS	200
LGTQTYICNV	NHKPSNTKVD	KKVEPKSCDK	THTCPPCPAP	ELLGGPSVFL	250
FPPKPKDTLM	ISRTPVETCV	VVDVSHEDPE	VKFNWYVDGV	EVHNAKTKPR	300
EEQYNSTYRV	VSVLTVLHQD	WLNKGKEYCK	VSNKALPAPI	EKTISKAKGQ	350
PREPQVYTL	PSRDELTKNQ	VSLTCLVKGF	YPSDIAVEWE	SNGQPENNYK	400
TTTPVLDSDG	SFFLYSKLT	DKSRWQGNV	FSCSVMHEAL	HNHYTQKSL	450
LSPGK					455

Light chain / Chaîne légère / Cadena ligera

AIQLTQSPSS	LSASVGDRVT	ITCRADESVR	TLMHWYQKPK	GKAPKLLIYL	50
VNSEIGVPD	RFGSGSGSTD	FRLTISSLQP	EDFATYYCQQ	TWSDPWFVFG	100
GTKVEIKRTV	AAPSVFIFPP	SDEQLKSGTA	SVVCLLNNFY	PREAKVQWKV	150
DNALQSGNSQ	ESVTEQDSKD	STYLSLSTLT	LKADYEKHK	VYACEVTHQG	200
LSSPVTKSFN	RGEC				214

Disulfide bridges location / Position des ponts disulfure / Posiciones de los puentes disulfuro

Intra-H (C23-C104)	22-96	152-208	269-329	375-433
	22"-96"	152"-208"	269"-329"	375"-433"
Intra-L (C23-C104)	23'-88'	134'-194'		
	23'''-88'''	134'''-194'''		
Inter-H-L (h 5-CL 126)	228-214'	228"-214"		
Inter-H-H (h 11, h 14)	234-234"	237-237"		

N-glycosylation sites / Sites de N-glycosylation / Posiciones de N-glicosilación

H CH2 N84.4:
305, 305"

bococizumabum #
bococizumab

immunoglobulin G2-kappa, anti-[*Homo sapiens* PCSK9 (proprotein convertase subtilisin/kexin type 9, neural apoptosis-regulated convertase 1, NARC1, NARC-1, proprotein convertase 9, PC9)], humanized monoclonal antibody;
gamma2 heavy chain (1-444) [humanized VH (*Homo sapiens* IGHV1-46*01 (90.80%) -(IGHD)-IGHJ1*01 L123>T (113)) [8.8.11] (1-118) -*Homo sapiens* IGHG2*01 (CH1 (119-216), hinge (217-228), CH2 A115>S (327), P116>S (328) (229-337), CH3 (338-442), CHS (443-444)) (119-444)], (132-214')-disulfide with kappa light chain (1'-214') [humanized V-KAPPA (*Homo sapiens* IGKV1-13*02 (91.00%) -IGKJ2*01 [6.3.9] (1'-107') -*Homo sapiens* IGKC*01 (108'-214')]; dimer (220-220":221-221":224-224":227-227")]-tetrakisdisulfide

bococizumab

immunoglobuline G2-kappa, anti-[*Homo sapiens* PCSK9 (proprotéine convertase subtilisine/kexine type 9, convertase 1 régulée par l'apoptose neuronale, NARC1, NARC-1, proprotéine convertase 9, PC9)], anticorps monoclonal humanisé;
chaîne lourde gamma2 (1-444) [VH humanisé (*Homo sapiens* IGHV1-46*01 (90.80%) -(IGHD)-IGHJ1*01 L123>T (113)) [8.8.11] (1-118) -*Homo sapiens* IGHG2*01 (CH1 (119-216), charnière (217-228), CH2 A115>S (327), P116>S (328) (229-337), CH3 (338-442), CHS (443-444)) (119-444)], (132-214')-disulfure avec la chaîne légère kappa (1'-214') [V-KAPPA humanisé (*Homo sapiens* IGKV1-13*02 (91.00%) -IGKJ2*01 [6.3.9] (1'-107') -*Homo sapiens* IGKC*01 (108'-214')]; dimère (220-220":221-221":224-224":227-227")]-tétrakisdisulfure

bococizumab

inmunoglobulina G2-kappa, anti-[*Homo sapiens* PCSK9 (proteína convertasa subtilisina/kexina tipo 9, convertasa 1 regulada por la apoptosis neuronal, NARC1, NARC-1, proteína convertasa 9, PC9)], anticuerpo monoclonal humanizado;
cadena pesada gamma2 (1-444) [VH humanizada (*Homo sapiens* IGHV1-46*01 (90.80%) -(IGHD)-IGHJ1*01 L123>T (113)) [8.8.11] (1-118) -*Homo sapiens* IGHG2*01 (CH1 (119-216), bisagra (217-228), CH2 A115>S (327), P116>S (328) (229-337), CH3 (338-442), CHS (443-444)) (119-444)], (132-214')-disulfuro con la cadena ligera kappa (1'-214') [V-KAPPA humanizada (*Homo sapiens* IGKV1-13*02 (91.00%) -IGKJ2*01 [6.3.9] (1'-107') -*Homo sapiens* IGKC*01 (108'-214')]; dímero (220-220":221-221":224-224":227-227")-tetrakisdisulfuro

Heavy chain / Chaîne lourde / Cadena pesada

QVQLVQSGAE VKKPGASVKV SCKASGYTFT SYMHWVRQA PGQGLEWMGE 50
ISPFGGRTNY NEKFKSRVTM TRDTSSTVY MELSSLRSED TAVYYCARER 100
PLYASDLWQ GTTVTVSSAS TKGPSVFPLA PCSRSTSEST AALGCLVKDY 150
FPEPVTWSN SGALTSGVHT FPAVLQSSGL YSLSSVTVTP SSNFGTQYIT 200
CNVDHKPSNT KVDKTVERRC CVECPFCFAP PVAGPSVFLF PFKPKDTLMI 250
SRPEVTCVV VDVSHEDPEV QFNWYVDGVE VHNATKPRE EQFNSTFRVV 300
SVLTVVHQDW LNGKEYKCKV SNKGLPSSIE KTISKTKGP REFQVYTLPP 350
SREEMTKNQV SLTCLVKGFY PSDIAVEWES NGQPENNYKT TTPMLDSDGS 400
FFLYSKLTVD KSRWQQGNVF SCSVMHEALH NHYTQKSLSL SPGK 444

Light chain / Chaîne légère / Cadena ligera

DIQMTQSPSS LSASVGRVT ITCRASQGIS SALAWYQQKP GKAPKLLIYS 50
ASYRYTGVPS RFGSGSGTD FTFITSSLPQ EDIATYYCQ RYSLWRTFGQ 100
GTKLEIKRTV AAPSVEIFPP SDEQLKSGTA SVVCLLNIFY PREAKVQNKV 150
DNALQSGNSQ ESVTEQDSKD STYSLSSILT LSKADYEKHK VYACEVTHQG 200
LSSPVTKSFN RGEC 214

Disulfide bridges location / Position des ponts disulfure / Posiciones de los puentes disulfuro

Intra-H (C23-C104) 22-96 145-201 258-318 364-422
22"-96" 145"-201" 258"-318" 364"-422"
Intra-L (C23-C104) 23'-88" 134'-194"
23'''-88''' 134'''-194'''
Inter-H-L (CH1 10-CL 126) 132"-214" 132"-214"
Inter-H-H (h 4, h 5, h 11, h 14) 220-220" 221-221" 224-224" 227-227"

N-glycosylation sites / Sites de N-glycosylation / Posiciones de N-glicosilación

H CH2 N84.4:
294, 294"

brincidofovirum**brincidofovir**

3-(hexadecyloxy)propyl hydrogen ({(1*S*)-1-[(4-amino-2-oxypyrimidin-1(2*H*)-yl)methyl]-2-hydroxyethoxy)methyl}phosphonate


brincidofovir

{{(1*S*)-1-[(4-amino-2-oxypyrimidin-1(2*H*)-yl)méthyl]-2-hydroxyethoxy)méthyl}hydrogénophosphonate de 3-(hexadécyloxy)propyle

brincidofovir

{{(1*S*)-1-[(4-amino-2-oxopirimidin-1(2*H*)-il)metil]-2-hidroxietoxi}metil}hidrógenofosfonato de 3-(hexadeciloxi)propilo

C₂₇H₅₂N₃O₇P



canoctakinum #

canoctakin

recombinant DNA derived, human interleukin 8 (CXCL8) mutein, produced in *Escherichia coli*:
[44,48,97,98-tetra-L-lysine]human interleukin 8 precursor-(34-99)-peptide

canoctakine

mutéine de l'interleukine 8 humaine (CXCL8), produite dans *Escherichia coli* à partir d'ADN recombinant:
[44,48,97,98-tétra-L-lysine]précurseur de l'interleukine 8 humaine-(34-99)-peptide

canoctakina

muteína de la interleukina 8 humana (CXCL8), producida en *Escherichia coli* a partir de ADN recombinante:
[44,48,97,98-tetra-L-lisina]precursor de la interleukina 8 humana-(34-99)-péptido

C₃₄₀H₅₆₅N₉₉O₉₄S₄

CQCIKTY SKPKHPKKIK 50
ELRVIESGPH CANTEIIVKL SDGRELCLDP KENWVQRVVE KFLKRAKKS 99
Disulfide bridges location / Position des ponts disulfure / Posiciones de los puentes disulfuro
34-61 36-77

censavudinum

censavudine


1-[(2*R*,5*R*)-5-ethynyl-5-(hydroxymethyl)-2,5-dihydrofuran-2-yl]-5-methylpyrimidine-2,4(1*H*,3*H*)-dione

censavudine

1-[(2*R*,5*R*)-5-éthynyl-5-(hydroxyméthyl)-2,5-dihydrofuran-2-yl]-5-méthylpyrimidine-2,4(1*H*,3*H*)-dione

censavudina

1-[(2*R*,5*R*)-5-etinil-5-(hidroximetil)-2,5-dihidrofuran-2-il]-5-metilpirimidina-2,4(1*H*,3*H*)-diona

C₁₂H₁₂N₂O₄**cimaglerminum alfa #**

cimaglermin alfa

recombinant DNA derived glial growth factor 2 (GGF2), produced in Chinese hamster ovary (CHO) cells (glycoform alfa):
[253-L-glutamine(R>Q variant 009307)]human pro-neuregulin-1 membrane-bound isoform 9 precursor-(51-422)-peptide

cimaglermine alfa

facteur de croissance 2 glial, produit par des cellules ovariennes de hamster chinois (glycoforme alfa):
[253-L-glutamine(R>Q variant 009307)]précurseur de l'isoforme 9 de la pro-neuréguline-1, se liant à la membrane, humain-(51-422)-peptide obtenu par culture de cellules ovariennes d'hamster chinois (CHO), glycoforme alfa

cimaglermina alfa

factor de crecimiento glial 2, producido por células ováricas de hamster chino (glicoforma alfa):
[253-L-glutamina(R>Q variante 009307)]precursor de la isoforma 9 de la pro-neuregulina-1, que se une a la membrana, humano-(51-422)-péptido obtenido por cultivo de células ováricas de hamster chino (CHO), glicoforma alfa

Sequence / Séquence / Secuencia

```

GNEAAPAGAS VCYSSPPSVG SVQELAQRAA VVIEGKVHPQ RRQQGALDRK 50
AAAAAGEAGA WGGDREPPAA GPRALGPPAE EPLLAANGTV PSWPTAPVPS 100
AGEPGEEAPY LVKVHQVWAV KAGGLKKDSL LTVRLGTWGH PAFPCGRLK 150
EDSRYIFFME PDANSTRAP AAFRASFPPL ETGRNLKKEV SRVLCRCAL 200
PPQLKEMKSQ ESAAGSKLVL RCETSSEYSS LRFKWFKNEN ELNRKNKPQN 250
IKIQKKPKGS ELRINKASLA DSGEYMCKVI SKLGNDASA NITIVESNAT 300
STSTTGTSHL VKCAEKEKTF CVNGGECFV KDLSNPSRYL CKCPNEFTGD 350
RCQNYVMASF YSTSTPFLLS PE 372

```

Disulfide bridges location / Position des ponts disulfure / Posiciones de los puentes disulfuro
 12-146 195-198 222-277 313-327 321-341 343-352

Glycosylation sites (N) / Sites de glycosylation (N) / Posiciones de glicosilación (N)
 Asn-87 Asn-164 Asn-285 Asn-291 Asn-298

cipargaminum

cipargamin


(1'*R*,3'*S*)-5,7'-dichloro-6'-fluoro-3'-methyl-2',3',4',9'-
 tetrahydrospiro[indole-3,1'-pyrido[3,4-*b*]indol]-2(1*H*)-one

cipargamine

(1'*R*,3'*S*)-5,7'-dichloro-6'-fluoro-3'-méthyl-2',3',4',9'-
 tétrahydrospiro[indole-3,1'-pyrido[3,4-*b*]indol]-2(1*H*)-one

cipargamina

(1'*R*,3'*S*)-5,7'-dicloro-6'-fluoro-3'-metil-2',3',4',9'-tetrahydrospiro[indol-
 3,1'-pirido[3,4-*b*]indol]-2(1*H*)-ona

C₁₉H₁₄Cl₂FN₃O**dapirolizumabum pegolum #**

dapirolizumab pegol

immunoglobulin Fab' G1-kappa pegylated, anti-[*Homo sapiens* CD40LG (CD40 ligand, CD40L, tumor necrosis factor ligand superfamily member 5, TNFSF5, tumor necrosis factor related activation protein, TRAP, CD154)], pegylated humanized monoclonal antibody;
 gamma1 heavy chain fragment VH-(CH1-hinge) (1-229) [humanized VH (*Homo sapiens* IGHV3-74*01 (76.50%) -(IGHD)-IGHJ1*01) [8.7.12] (1-118) -*Homo sapiens* IGHG1*01 (CH1 (119-216), hinge 1-11 (217-227)) (119-227) -dialanyl (228-229)], (221-214')-disulfide with kappa light chain (1'-214') [humanized V-KAPPA (*Homo sapiens* IGKV1-NL1*01 (83.20%) -IGKJ1*01) [6.3.9] (1'-107') -*Homo sapiens* IGKC*01 (108'-214')]; conjugated via a linker of the maleimide group (thioether bond with cysteinyl h 11 (227)) to two linear chains of methoxy polyethylene glycol 20 (mPEG20).

dapirolizumab pégol

immunoglobuline Fab' G1-kappa pégylé, anti-[*Homo sapiens* CD40LG (CD40 ligand, CD40L, membre 5 de la superfamille des ligands facteurs de nécrose tumorale, TNFSF5, protéine d'activation apparentée au facteur de nécrose tumorale, TRAP, CD154)], anticorps monoclonal humanisé pégylé; fragment VH-(CH1-charnière) de la chaîne lourde gamma1 (1-229) [VH humanisé (*Homo sapiens* IGHV3-74*01 (76.50%) -(IGHD)-IGHJ1*01) [8.7.12] (1-118) -*Homo sapiens* IGHG1*01 (CH1 (119-216), charnière 1-11 (217-227)) (119-227) -dialanyl (228-229)], (221-214')-disulfure avec la chaîne légère kappa (1'-214') [V-KAPPA humanisé (*Homo sapiens* IGKV1-NL1*01 (83.20%) -IGKJ1*01) [6.3.9] (1'-107') -*Homo sapiens* IGKC*01 (108'-214')]; conjugué via un linker du groupe maléimide (liaison thioéther avec cystéinyl h 11 (227)) à deux chaînes linéaires de méthoxy polyéthylène glycol 20 (mPEG20).

dapirolizumab pegol

immunoglobulina Fab' G1-kappa pegilada, anti-[*Homo sapiens* CD40LG (ligando CD40, CD40L, miembro 5 de la superfamilia de ligandos factores de necrosis tumoral, TNFSF5, proteína de activación relacionada con el factor de necrosis tumoral, TRAP, CD154)], anticuerpo monoclonal humanizado pegilado; fragmento VH-(CH1-bisagra) de la cadena pesada gamma1 (1-229) [VH humanizado (*Homo sapiens* IGHV3-74*01 (76.50%) -(IGHD)-IGHJ1*01) [8.7.12] (1-118) -*Homo sapiens* IGHG1*01 (CH1 (119-216),bisagra 1-11 (217-227)) (119-227) -dialanil (228-229)], (221-214')-disulfuro con la cadena ligera kappa (1'-214') [V-KAPPA humanizado (*Homo sapiens* IGKV1-NL1*01 (83.20%) -IGKJ1*01) [6.3.9] (1'-107') -*Homo sapiens* IGKC*01 (108'-214')]; conjugado mediante un conector del grupo maleimida (enlace tioéter con cisteinil h 11 (227)) a dos cadenas lineales de metoxi polietilen glicol 20 (mPEG20)

Heavy chain / Chaîne lourde / Cadena pesada
 EVQLVESGGG LVQPGGSLRL SCAVSGFSST NYHVHWVRQA PGKGLEWMGV 50
 IWGDGDTSYN SVLKSRFTIS RDTSKNTVYL QMNSLRAEDT AVYYCARQLT 100
 HYYVLAAGWQ GTLVTVSSAS TKGPSVFPLA PSSKSTSGGT AALGCLVKDY 150
 FPEPVTVSWN SGALTSGVHT FPAVLQSSGL YSLSSVVTVP SSSLGTQTYI 200
 CNVNHKPSNT KVDKKVEPKS CPKTHTCOA 229

Light chain / Chaîne légère / Cadena ligera
 DIQMTQSPSS LSASVGRVT ITCRASEDLV YNLAWYQRKP GKAPKLLIYD 50
 TYRLADGVPS RFGSGSGSTD YTLTISSLQP EDFASYCQQ YYKFFFTFGQ 100
 GTKVEIKRTV AAPSVFIFPP SDEQLKSGTA SVVCLLNNFY PREAKVQWVK 150
 DNALQSGNSQ ESVTEQDSKD STYSLSSLT LSKADYEKKH VYACEVTHQG 200
 LSSPVTKSFN RGEK 214

Disulfide bridges location / Position des ponts disulfure / Posiciones de los puentes disulfuro
 Intra-H (C23-C104) 22-95 145-201
 Intra-L (C23-C104) 23'-88' 134'-194'
 Inter-H-L (h 5-CL 126) 221-214'

N-glycosylation sites / Sites de N-glycosylation / Posiciones de N-glicosilación
 None

Pegylation site / Site de pegylation / Posición de pegilación
 C
 227

dasotralinum
dasotraline


(1*R*,4*S*)-4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydronaphthalen-1-amine

dasotraline

(1*R*,4*S*)-4-(3,4-dichlorophényl)-1,2,3,4-tétrahydronaphthalén-1-amine

dasotralina

(1*R*,4*S*)-4-(3,4-diclorofenil)-1,2,3,4-tetrahidronaftalen-1-amina

C₁₆H₁₅Cl₂N**decernotinibum**


decernotinib

(2*R*)-2-methyl-2-[[2-(1*H*-pyrrolo[2,3-*b*]pyridin-3-yl)pyrimidin-4-yl]amino]-*N*-(2,2,2-trifluoroethyl)butanamide

décernotinib

(2*R*)-2-méthyl-2-[[2-(1*H*-pyrrolo[2,3-*b*]pyridin-3-yl)pyrimidin-4-yl]amino]-*N*-(2,2,2-trifluoroéthyl)butanamide

decernotinib

(2*R*)-2-metil-2-[[2-(1*H*-pirrolo[2,3-*b*]piridin-3-il)pirimidin-4-il]amino]-*N*-(2,2,2-trifluoroetil)butanamidaC₁₈H₁₉F₃N₆O**deldeprevirum**

deldeprevir



(2*R*,6*R*,12*Z*,13*aS*,14*aR*,16*aS*)-*N*-(cyclopropanesulfonyl)-6-[2-(3,3-difluoropiperidin-1-yl)-2-oxoethyl]-2-({7-methoxy-8-methyl-2-[4-(propan-2-yl)-1,3-thiazol-2-yl]quinolin-4-yl}oxy)-5,16-dioxo-1,2,3,6,7,8,9,10,11,13*a*,14,15,16,16*a*-tetradecahydrocyclopropa[*e*]pyrrolo[1,2-*a*][1,4]diazacyclopentadecine-14*a*(5*H*)-carboxamide

deldéprévîr

(2*R*,6*R*,12*Z*,13*aS*,14*aR*,16*aS*)-*N*-(cyclopropanesulfonyl)-6-[2-(3,3-difluoropipéridin-1-yl)-2-oxoéthyl]-2-({7-méthoxy-8-méthyl-2-[4-(propan-2-yl)-1,3-thiazol-2-yl]quinoléin-4-yl}oxy)-5,16-dioxo-1,2,3,6,7,8,9,10,11,13*a*,14,15,16,16*a*-tétradécahydrocyclopropa[*e*]pyrrolo[1,2-*a*][1,4]diazacyclopentadécine-14*a*(5*H*)-carboxamide

deldeprevir

(2*R*,6*R*,12*Z*,13*aS*,14*aR*,16*aS*)-*N*-(cicopropanosulfonyl)-6-[2-(3,3-difluoropiperidin-1-il)-2-oxoetil]-2-({8-metil-7-metoxi-2-[4-(propan-2-il)-1,3-tiazol-2-il]quinolin-4-il}oxi)-5,16-dioxo-1,2,3,6,7,8,9,10,11,13*a*,14,15,16,16*a*-tetradecahidrociclopropa[*e*]pirrolo[1,2-*a*][1,4]diazaciclopentadecina-14*a*(5*H*)-carboxamida



duligotuzumabum #
duligotuzumab

immunoglobulin G1-kappa, anti-[*Homo sapiens* ERBB3 (receptor tyrosine-protein kinase erbB-3, HER3)], humanized monoclonal antibody;
gamma1 heavy chain (1-451) [humanized VH (*Homo sapiens*IGHV3-74*01 (82.70%) -(IGHD)-IGHJ4*01) [8.8.14] (1-121) -IGHG1*03 CH1 R120>K (218) (122-451)], (224-214')-disulfide with kappa light chain (1'-214') [humanized V-KAPPA (*Homo sapiens*IGKV1-39*01 (87.40%) -IGKJ2*01 L124>V (104)) [6.3.9] (1'-107') -IGKC*01 (108'-214')]; dimer (230-230":233-233")-bisdisulfide

duligotuzumab

immunoglobuline G1-kappa, anti-[*Homo sapiens* ERBB3 (récepteur tyrosine-protéine kinase erbB3, HER3)], anticorps monoclonal humanisé;
chaîne lourde gamma1 (1-451) [VH humanisé (*Homo sapiens*IGHV3-74*01 (82.70%) -(IGHD)-IGHJ4*01) [8.8.14] (1-121) -IGHG1*03 CH1 R120>K (218) (122-451)], (224-214')-disulfure avec la chaîne légère kappa (1'-214') [V-KAPPA humanisé (*Homo sapiens*IGKV1-39*01 (87.40%) -IGKJ2*01 L124>V (104)) [6.3.9] (1'-107') -IGKC*01 (108'-214')]; dimère (230-230":233-233")-bisdisulfure

duligotuzumab

inmunoglobulina G1-kappa, anti-[*Homo sapiens* ERBB3 (receptor tirosina-proteína kinasa erbB3, HER3)], anticuerpo monoclonal humanizado;
cadena pesada gamma1 (1-451) [VH humanizado (*Homo sapiens*IGHV3-74*01 (82.70%) -(IGHD)-IGHJ4*01) [8.8.14] (1-121) -IGHG1*03 CH1 R120>K (218) (122-451)], (224-214')-disulfuro con la cadena ligera kappa (1'-214') [V-KAPPA humanizado (*Homo sapiens*IGKV1-39*01 (87.40%) -IGKJ2*01 L124>V (104)) [6.3.9] (1'-107') -IGKC*01 (108'-214')]; dímero (230-230":233-233")-bisdisulfuro

Heavy chain / Chaîne lourde / Cadena pesada			
EVQLVESGGG	LVQPFGSLRL	SCAASGFTLS	GDWIIHWVRQA PGKGLEWVGE 50
ISAAGGYTDY	ADSVKGRFTI	SADTSKNTAY	LQMNSLRAED TAVYYCARES 100
RVSFEAAMDY	WGQGLTVTVS	SASTKGPSVF	PLAPSSKSTS GGTAALGCLV 150
KDYFFPEPTV	SWNSGALTSG	VHTFFPAVLQS	SGLYSLSSVV TVPSSSLGTQ 200
TYICNVNHKP	SNTKVDKKVE	PKSCDKHTHC	PPCPAPELLG GPSVFLFFPK 250
PKDTLMISRT	FEVTCVVVDV	SHEDPEVKFN	WYVDGVEVHN AKTKPREEQY 300
NSTYRVVSVL	TVLHQDWLNG	KEYKCKVSNK	ALPAPIEKTI SKAKGQPREP 350
QVYTLPPSRE	EMTKNQVSLT	CLVKGFYPSD	IAVEWESNGQ PENNYKTPP 400
VLDSDGSFFL	YSKLTVDKSR	WQQGNVFCSS	VMHEALHNHY TQKSLSLSPG 450
K 451			
Light chain / Chaîne légère / Cadena ligera			
DIQMTQSPSS	LSASVGDRTV	ITCRASQNI	TDVAWYQQKP GKAPKLLIYS 50
ASFLYSGVPS	RFGSGSGGTD	FTLTISSLQP	EDFATYYCQQ SEPEPYTFGQ 100
GTKVEIKRTV	AAPSVFIFFP	SDEQLKSGTA	SVVCLLNIFY PREAKVQWKV 150
DNALQSGNSQ	ESVTEQDSKD	STYLSSTLT	LSKADYEKHK VYACEVTHQG 200
LSSPVTKSFN RGEK 214			
Disulfide bridges location / Position des ponts disulfure / Posiciones de los puentes disulfuro			
Intra-H	22-96	148-204	265-325 371-429
	22"-96"	148"-204"	265"-325" 371"-429"
Intra-L	23'-88'	134'-194'	
	23'''-88'''	134'''-194'''	
Inter-H-L	224-214'	224"-214"	
Inter-H-H	230-230"	233-233"	
N-glycosylation sites / Sites de N-glycosylation / Posiciones de N-glicosilación			
H CH2 N84.4:			
301, 301"			

duvelisibum
duvelisib

8-chloro-2-phenyl-3-[(1*S*)-1-(7*H*-purin-6-ylamino)ethyl]isoquinolin-1(2*H*)-one


duvélisib

8-chloro-2-phényl-3-[(1*S*)-1-(7*H*-purin-6-ylamino)éthyl]isoquinoléin-1(2*H*)-one

duvelisib

8-cloro-2-fenil-3-[(1*S*)-1-(7*H*-purin-6-ilamino)etil]isoquinolein-1(2*H*)-ona

C₂₂H₁₇ClN₆O



eftrenonacogum alfa #
eftrenonacog alfa

recombinant DNA derived human blood coagulation factor IX fusion protein with one Fc fragment of the human immunoglobulin G1 Fc fragment dimer, produced in HEK293H cells (glycoform alfa): human blood coagulation factor IX (EC 3.4.21.22, Christmas factor, plasma thromboplastin component) variant 148-T, fusion protein with human immunoglobulin G1 Fc fragment (IGHG1*01 H-CH2-CH3)-(6-231)-peptide (421-6':424-9')-bisdisulfide with human immunoglobulin G1 Fc fragment (IGHG1*01 H-CH2-CH3)-(6-231)-peptide

eftrénonacog alfa

protéine de fusion entre le facteur IX de coagulation sanguine humain et l'un des fragments du dimère du fragment Fc de l'immunoglobuline G1 humaine, produite par des cellules HEK293H à partir d'ADN recombinant (glycoforme alfa) : variant 148-T du facteur IX de coagulation humaine (EC 3.4.21.22, facteur Christmas, thromboplastine composant du plasma) protéine de fusion avec le fragment Fc de l'immunoglobuline G1 humaine (IGHG1*01 H-CH2-CH3)-(6-231)-peptide (421-6':424-9')-bisdisulfure avec le fragment Fc de l'immunoglobuline G1 humaine (IGHG1*01 H-CH2-CH3)-(6-231)-peptide

eftrenonacog alfa


proteína de fusión entre el factor IX de coagulación humano y uno de los fragmentos del dímero del fragmento Fc de la inmunoglobulina G1 humana, producida por células HEK293H a partir de ADN recombinante (glicofoma alfa) : variante 148-T del factor IX de coagulación humana (EC 3.4.21.22, factor Christmas, tromboplastina componente del plasma) proteína de fusión con el fragmento Fc de la inmunoglobulina G1 humana (IGHG1*01 H-CH2-CH3)-(6-231)-péptido (421-6':424-9')-bisdisulfuro con el fragmento Fc de l'inmunoglobulina G1 humana (IGHG1*01 H-CH2-CH3)-(6-231)-péptido

Fusion protein/ Protéine de fusion / Proteína de fusión
 YNSKLEEFV QGNLREOME EKCSFEARE VPENTERTTE FWKQVVDGQ 50
 CESNPCLNGG SCKDDINSYE CWCPFGFEGK NCBLDVTCTN KNGRCEQFC 100
 NSADNKKVCS CTEGYRLAEN QKSCPAVVF PCGRVSVSQT SKLTRAETVF 150
 PDVDYVNSTE AETILDNITQ STQSFNDPTR VVGEDAKPG QFFWQVVLNG 200
 KVDAFCGGSI VNEKWIIVTAA HCVETGVKIT VVAGEHNIEE TEHTQKRN 250
 IRIIPHHNIN AAINKYNHDI ALLELDEPLV LNSYVTPICI ADKEYTNIFL 300
 KFGSGYVSGW GRVFKHGRSA LVLQYLRVPL VDRATCLRST KFTIYNNMFC 350
 AGFHEGGRDS CQGDGGGPHV TEVEGTSFLT GIISWGECA MRGKYGITK 400
 VSRVNVNIKE KTKLTDKTHT CPPCPAPELL GGPSVFLFPP KPKDILMISR 450
 TEVTCVVDV VSHEDPEVKF NWYVDGVEVH NAKTKFREEQ YNSTIRVSV 500
 LTVLHQDWLN GVEYKCKVSN KALPAIEKT ISKAKGQFRE EQVITLPPSR 550
 DELTKNQVSL TCLVKGFYPS DIAVEWESNG QPENNYKTFP PULDSGGSFF 600
 LYSKLTVDKS RWQGNVFSC SVMHEALHNH YTKSLSLSP G 641

Immunoglobulin Fc fragment / Fragment Fc de l'immunoglobuline / Fragmento Fc de la inmunoglobulina
 DKHTCTPCPC APELLGGPSV FLFPPKPKDT LMISRTPEVT CVVVDVSHED 50'
 PEVKFNWYVD GVEVHNAKT PREEQYNSTY RVSVTLTVLH QDWLNGKEYK 100'
 CKVSNKALPA PIEKTISKAK GQPREPQVYT LPFSRDELTK NQVSLTCLVK 150'
 GFYPSDIAVE WESNGQPENN YKTTFPVLDL DGSFFLYSKL TVDKSRWQGG 200'
 NVFSCSVME ALHNHYTQKS LSLSPG 226'

Disulfide bridges location / Position des ponts disulfure / Posiciones de los puentes disulfuro
 6'-421 9'-424 18-23 41'-101' 51-62 56-71 73-82 88-99 95-109
 111-124 132-289 147'-205' 206-222 336-350 361-389 456-516 562-620

Modified residues / Résidus modifiés / Restos modificados



Glycosylation sites (N, S, T) / Sites de glycosylation (N, S, T) / Posiciones de glicosilación (N, S, T)

Ser-53* Ser-61* Asn-77' Asn-157 Thr-159* Asn-167 Thr-169* Asn-492
 * partially modified / modifiés en partie / parcialmente modificados

elbasvirum
elbasvir


dimethyl *N,N'*-([(6*S*)-6-phenyl-6*H*-indolo[1,2-*c*][1,3]benzoxazine-3,10-diyl]bis(1*H*-imidazole-5,2-diyl-(2*S*)-pyrrolidine-2,1-diyl[(2*S*)-3-methyl-1-oxobutane-1,2-diyl]))biscarbamate

elbasvir

N,N'-([(6*S*)-6-phényl-6*H*-indolo[1,2-*c*][1,3]benzoxazine-3,10-diyl]bis(1*H*-imidazole-5,2-diyl-(2*S*)-pyrrolidine-2,1-diyl[(2*S*)-3-méthyl-1-oxobutane-1,2-diyl]))biscarbamate de diméthyle

elbasvir

N,N'-([[(6*S*)-6-fenil-6*H*-indolo[1,2-*c*][1,3]benzoxazina-3,10-diil]bis{1*H*-imidazole-5,2-diil-(2*S*)-pirrolidina-2,1-diyl}[(2*S*)-3-metil-1-oxobutano-1,2-diil]})biscarbamato de dimetilo

C₄₉H₅₅N₉O₇**entosobulinum**

entosobulin


2-{1-[(4-chlorophenyl)methyl]-1*H*-indol-3-yl}-2-oxo-*N*-(quinolin-6-yl)acetamide

entosobuline

2-{1-[(4-chlorophényl)méthyl]-1*H*-indol-3-yl}-2-oxo-*N*-(quinoléin-6-yl)acétamide

entosobulina

2-{1-[(4-clorofenil)metil]-1*H*-indol-3-il}-2-oxo-*N*-(quinolein-6-il)acetamida

C₂₆H₁₈ClN₃O₂**entospletinibum**

entospletinib


6-(1*H*-indazol-6-yl)-*N*-[4-(morpholin-4-yl)phenyl]imidazo[1,2-*a*]pyrazin-8-amine

entosplétinib

6-(1*H*-indazol-6-yl)-*N*-[4-(morpholin-4-yl)phényl]imidazo[1,2-*a*]pirazin-8-amine

entospletinib

6-(1*H*-indazol-6-il)-*N*-[4-(morfolin-4-il)fenil]imidazo[1,2-*a*]pirazin-8-amina

C₂₃H₂₁N₇O**etiguanfacinum**

etiguanfacine



ethyl *N*-{[2-(2,6-dichlorophenyl)acetyl]carbamidoyl}carbamate

étiguanfacine

N-{[2-(2,6-dichlorophényl)acétyl]carbamidoyl}carbamate d'éthyle

etiguanfacina

N-{[2-(2,6-diclorofenil)acetil]carbamidoi}carbamato de etilo



ferricum derisomaltosum
ferric derisomaltose

dérisomaltose ferrique


derisomaltosa férrica

(1→6)-α-D-glucopyranan-(1→6)-D-glucitol iron(III) complex

complexe de fer(III) et de (1→6)-α-D-glucopyranan-(1→6)-D-glucitol

complejo hierro(III) (1→6)-α-D-glucopiranan-(1→6)-D-glucitol

(C₆H₁₁O₅)(C₆H₁₀O₅)_n(C₆H₁₃O₅) Fe^{III} complex (*n* = 4.2)



fimaporfinum
fimaporfin



fimaporfine

fimaporfina

4,4'-(15,20-diphenyl-7,8(or 12,13 or 17,18)-dihydro-21*H*,23*H*-porphine-5,10-diyl)bisbenzenesulfonic acid, mixture of three isomers A, B and C (25%,50%,25%)

acide 4,4'-(15,20-diphényl-7,8(ou 12,13 ou 17,18)-dihydro-21*H*,23*H*-porphine-5,10-diyl)bisbenzènesulfonique, mélange de trois isomères A, B et C (25%,50%,25%)

ácido 4,4'-(15,20-difenil-7,8(o 12,13 o 17,18)-dihidro-21*H*,23*H*-porfirina-5,10-diil)bisbencenosulfónico, mezcla de tres isómeros A, B y C (50%,25%,25%)



fletikumabum #

fletikumab

immunoglobulin G4-kappa, anti-[*Homo sapiens* IL20 (interleukin 20, IL-20)], human monoclonal antibody;
gamma4 heavy chain (1-454) [*Homo sapiens* VH (IGHV1-3*01 (88.80%) -(IGHD)-IGHJ6*01 [8.8.20] (1-127) -IGHG4*01 (CH1 (128-225), hinge S10>P (235) (226-237), CH2 (238-347), CH3 (348-452), CHS (453-454)) (128-454))], (141-214')-disulfide with kappa light chain (1'-214') [*Homo sapiens* (V-KAPPA (IGKV1-13*02 (100.00%) -IGKJ4*01 [6.3.9] (1'-107') -IGKC*01 (108'-214'))]; dimer (233-233":236-236")-bisdisulfide

flétikumab

immunoglobuline G4-kappa, anti-[*Homo sapiens* IL20 (interleukine 20, IL-20)], anticorps monoclonal humain;
chaîne lourde gamma4 (1-454) [*Homo sapiens* VH (IGHV1-3*01 (88.80%) -(IGHD)-IGHJ6*01 [8.8.20] (1-127) -IGHG4*01 (CH1 (128-225), charnière S10>P (235) (226-237), CH2 (238-347), CH3 (348-452), CHS (453-454)) (128-454))], (141-214')-disulfure avec la chaîne légère kappa (1'-214') [*Homo sapiens* (V-KAPPA (IGKV1-13*02 (100.00%) -IGKJ4*01 [6.3.9] (1'-107') -IGKC*01 (108'-214'))]; dimère (233-233":236-236")-bisdisulfure

fletikumab

immunoglobulina G4-kappa, anti-[*Homo sapiens* IL20 (interleukina 20, IL-20)], anticuerpo monoclonal humano;
cadena pesada gamma4 (1-454) [*Homo sapiens* VH (IGHV1-3*01 (88.80%) -(IGHD)-IGHJ6*01 [8.8.20] (1-127) -IGHG4*01 (CH1 (128-225), bisagra S10>P (235) (226-237), CH2 (238-347), CH3 (348-452), CHS (453-454)) (128-454))], (141-214')-disulfuro con la cadena ligera kappa (1'-214') [*Homo sapiens* (V-KAPPA (IGKV1-13*02 (100.00%) -IGKJ4*01 [6.3.9] (1'-107') -IGKC*01 (108'-214'))]; dímero (233-233":236-236")-bisdisulfuro

Heavy chain / Chaîne lourde / Cadena pesada

QVQLVQSGAE	VKRPGASVKV	SCKASGYTFT	NDIIHWVRQA	PGQRLEWMGW	50
INAGYGNTRY	SQNFQDRVSI	TRDTSASTAY	MELISLRSED	TAVYYCAREP	100
LWFGESEPHD	YYGMDVWGQ	TTVTSSAST	KGPSVFPLAP	CSRSTSESTA	150
ALGCLVKDYF	PEPVTVSWNS	GALTSGVHTF	PAVLQSSGLY	SLSSVVTVP	200
SSLGTTKTYC	NVDHKPSNTK	VDRKRVESKY	PPCPPCPAPE	FLGGFVSFLP	250
PPKPKDTLMI	SRTPEVTCVV	VDVSQEDPEV	QFNWYVDGVE	VHNAKTKPRE	300
EQPNSTYRVV	SVLTIVLHQDW	LNKEYKCKV	SNKGLPSSIE	KTISKAKGQP	350
REFQVYTLPP	SQEQMTKNQV	SLTCLVKGFY	PSDIAVEWES	NGQPENNYKT	400
TPPVLDSDGS	FFLYSRLTVD	KSRWQEGNVF	SCSVMEALH	NHYTQKSLSL	450
SLGK					454

Light chain / Chaîne légère / Cadena ligera

AIQLTQSPSS	LSASVGDRTV	ITCRASQGIS	SALAWYQQKP	GKAPKLLIYD	50
ASSLESGVPS	RFGSGSGGTG	FTLTISLQP	EDFATYYCQQ	FNSYPLTFGG	100
GTKVEIKRTV	AAPSVFIFFP	SDEQLKSGTA	SVVCLLNNFY	PREAKVQWVK	150
DNALQSGNSQ	ESVTEQDSKD	STYSLSTLT	LSKADYEKHK	VYACEVTHQG	200
LSSPVTKSFN	RGEC				214

Disulfide bridges location / Position des ponts disulfure / Posiciones de los puentes disulfuro

Intra-H (C23-C104)	22-96	154-210	268-328	374-432
	22"-96"	154"-210"	268"-328"	374"-432"
Intra-L (C23-C104)	23'-88'	134'-194'		
	23'''-88'''	134'''-194'''		
Inter-H-L (CH1 10-CL 126)	141-214'	141"-214"		
Inter-H-H (h 8, h 11)	233-233"	236-236"		

N-glycosylation sites / Sites de N-glycosylation / Posiciones de N-glicosilación

H CH2 N84.4:
304, 304"

fosravuconazolium


fosravuconazole

{{(1*R*,2*R*)-2-[4-(4-cyanophenyl)-1,3-thiazol-2-yl]-1-(2,4-difluorophenyl)-1-[(1*H*-1,2,4-triazol-1-yl)methyl]propoxy)methyl}methyl dihydrogen phosphate

fosravuconazole

dihydrogénophosphate de {{(1*R*,2*R*)-2-[4-(4-cyanophényl)-1,3-thiazol-2-yl]-1-(2,4-difluorophényl)-1-[(1*H*-1,2,4-triazol-1-yl)méthyl]propoxy)méthyle


fosravuconazol

dihidrógenofosfato de {(1*R*,2*R*)-2-[4-(4-cianofenil)-1,3-tiazol-2-il]-1-(2,4-difluorofenil)-1-[(1*H*-1,2,4-triazol-1-il)metil]propoxi}metilo $C_{23}H_{20}F_2N_5O_5PS$ gemilukastum
gemilukast4,4'-[4-fluoro-7-(2-{4-[4-(3-fluoro-2-methylphenyl)butoxy]phenyl}ethynyl)-2-methyl-1*H*-indole-1,3-diyl]dibutanoic acid

gémilukast

acide 4,4'-[4-fluoro-7-(2-{4-[4-(3-fluoro-2-méthylphényl)butoxy]phényl}éthynyl)-2-méthyl-1*H*-indole-1,3-diyl]dibutanoïque


gemilukast

ácido 4,4'-[4-fluoro-7-(2-{4-[4-(3-fluoro-2-metilfenil)butoxi]fenil}etinil)-2-metil-1*H*-indol-1,3-diil]dibutanoico $C_{36}H_{37}F_2NO_5$ grapiprantum
grapiprant*N*-{2-[4-(2-ethyl-4,6-dimethyl-1*H*-imidazo[4,5-*c*]pyridin-1-yl)phenyl]ethyl}-*N'*-[(4-methylphenyl)sulfonyl]urea

grapiprant

N-{2-[4-(2-éthyl-4,6-diméthyl-1*H*-imidazo[4,5-*c*]pyridin-1-yl)phényl]éthyl}-*N'*-[(4-méthylphényl)sulfonyl]urée

grapiprant

N-{2-[4-(2-etil-4,6-dimetil-1*H*-imidazo[4,5-*c*]piridin-1-il)fenil]etil}-*N'*-[(4-metilfenil)sulfonyl]urea $C_{26}H_{29}N_5O_3S$ 

grazoprevirum
grazoprevir


(1*aR*,5*S*,8*S*,10*R*,22*aR*)-5-*tert*-butyl-*N*-{[(1*R*,2*S*)-1-[(cyclopropylsulfonyl)carbamoyl]-2-ethenylcyclopropyl]-14-methoxy-3,6-dioxo-1,1*a*,3,4,5,6,9,10,18,19,20,21,22,22*a*-tetradecahydro-8*H*-7,10-methanocyclopropa[18,19][1,10,3,6]dioxadiazacyclononadecino[11,1-*b*]quinoxaline-8-carboxamide

grazoprévir

(1*aR*,5*S*,8*S*,10*R*,22*aR*)-5-*tert*-butyl-*N*-{[(1*R*,2*S*)-1-[(cyclopropylsulfonyl)carbamoyl]-2-éthénylcyclopropyl]-14-méthoxy-3,6-dioxo-1,1*a*,3,4,5,6,9,10,18,19,20,21,22,22*a*-tétradécahydro-8*H*-7,10-méthanocyclopropa[18,19][1,10,3,6]dioxadiazacyclononadécino[11,1-2-*b*]quinoxaline-8-carboxamide

grazoprevir

(1*aR*,5*S*,8*S*,10*R*,22*aR*)-5-*terc*-butil-*N*-{[(1*R*,2*S*)-1-[(ciclopropilsulfonyl)carbamoi]-2-etenilciclopropil]-14-metoxi-3,6-dioxo-1,1*a*,3,4,5,6,9,10,18,19,20,21,22,22*a*-tetradecahidro-8*H*-7,10-metanociclopropa[18,19][1,10,3,6]dioxadiazaciclonoanadecino[11,12-*b*]quinoxalina-8-carboxamida

C₃₈H₅₀N₆O₉S**icosabutas**
icosabutate


rac-2-[(5*Z*,8*Z*,11*Z*,14*Z*,17*Z*)icosa-5,8,11,14,17-pentaen-1-yloxy]butanoic acid

icosabutate

acide *rac*-2-[(5*Z*,8*Z*,11*Z*,14*Z*,17*Z*)icosa-5,8,11,14,17-pentaén-1-yloxy]butanoïque

icosabutato

ácido *rac*-2-[(5*Z*,8*Z*,11*Z*,14*Z*,17*Z*)icosa-5,8,11,14,17-pentaen-1-iloxi]butanoico

C₂₄H₃₈O₃**idalopirdinum**
idalopirdine

2-(6-fluoro-1*H*-indol-3-yl)-*N*-{[3-(2,2,3,3-tetrafluoropropoxy)phenyl]methyl}ethanamine


idalopirdine

2-(6-fluoro-1*H*-indol-3-yl)-*N*-{[3-(2,2,3,3-tétrafluoropropoxy)phényl]méthyl}éthanamine

idalopirdine

2-(6-fluoro-1*H*-indol-3-yl)-*N*-{[3-(2,2,3,3-tétrafluoropropoxy)phényl]méthyl}éthanamine

idalopirdina

2-(6-fluoro-1*H*-indol-3-il)-*N*-{[3-(2,2,3,3-tétrafluoropropoxi)fenil]metil}etanamina $C_{20}H_{19}F_5N_2O$ **lefamulinum**


lefamulin

(3*aS*,4*R*,5*S*,6*S*,8*R*,9*R*,9*aR*,10*R*)-6-ethenyl-5-hydroxy-4,6,9,10-tetraméthyl-1-oxodécahydro-3*a*,9-propanocyclopenta[8]annulén-8-yl {[[(1*R*,2*R*,4*R*)-4-amino-2-hydroxycyclohexyl]sulfanyl}acétate

léfamuline

{[(1*R*,2*R*,4*R*)-4-amino-2-hydroxycyclohexyl]sulfanyl}acétate de (3*aS*,4*R*,5*S*,6*S*,8*R*,9*R*,9*aR*,10*R*)-6-éthényl-5-hydroxy-4,6,9,10-tétraméthyl-1-oxodécahydro-3*a*,9-propano-3*aH*-cyclopenta[8]annulén-8-yle

lefamulina

{[(1*R*,2*R*,4*R*)-4-amino-2-hidroxiciclohexil]sulfanil}acetato de (3*aS*,4*R*,5*S*,6*S*,8*R*,9*R*,9*aR*,10*R*)-6-etenil-5-hidroxi-4,6,9,10-tetrametil-1-oxodecahidro-3*a*,9-propanociclopenta[8]anulén-8-ilo $C_{28}H_{45}NO_5S$ **lerimazolinum**


lerimazoline

2-[(2,4,6-triméthylphényl)méthyl]-4,5-dihydro-1*H*-imidazole

lérimazoline

2-[(2,4,6-triméthylphényl)méthyl]-4,5-dihydro-1*H*-imidazole

lerimazolina

2-[(2,4,6-trimetilfenil)metil]-4,5-dihidro-1*H*-imidazol $C_{13}H_{18}N_2$ 

lifastuzumabum vedotinum #

lifastuzumab vedotin

immunoglobulin G1-kappa auristatin E conjugate, anti-[*Homo sapiens* SLC34A2 (solute carrier family 34 sodium phosphate member 2, sodium/phosphate cotransporter 2B, NaPi2b, NaPi3b)], humanized monoclonal antibody conjugated to auristatin E; gamma1 heavy chain (1-450) [humanized VH (*Homo sapiens* IGHV3-23*04 (85.70%) -(IGHD)-IGHJ5*01) [8.8.13] (1-120) -*Homo sapiens* IGHG1*03 (CH1 R120>K (217) (121-218), hinge (219-233), CH2 (234-343), CH3 (344-448), CHS (449-450)) (121-450)], (223-219')-disulfide with kappa light chain (1'-219') [humanized V-KAPPA (*Homo sapiens* IGKV1-39*01 (78.00%) -IGKJ1*01) [11.3.9] (1'-112') -*Homo sapiens* IGKC*01 (113'-219')]; dimer (229-229'':232-232'')-bisdisulfide; conjugated, on an average of 3 to 4 cysteinyl, to monomethylauristatin E (MMAE), via a cleavable maleimidocaproyl-valyl-citrullinyl-*p*-aminobenzyloxycarbonyl (mc-val-cit-PABC) type linker

For the vedotin part, please refer to the document "INN for pharmaceutical substances: Names for radicals, groups and others".

lifastuzumab védotine

immunoglobuline G1-kappa conjuguée à l'auristatine E, anti-[*Homo sapiens* SLC34A2 (membre 2 de la famille 34 sodium phosphate de transporteurs de solutés, cotransporteur 2B de sodium/phosphate, NaPi2b, NaPi3b)], anticorps monoclonal humanisé conjugué à l'auristatine E; chaîne lourde gamma1 (1-450) [VH humanisé (*Homo sapiens* IGHV3-23*04 (85.70%) -(IGHD)-IGHJ5*01) [8.8.13] (1-120) -*Homo sapiens* IGHG1*03 (CH1 R120>K (217) (121-218), charnière (219-233), CH2 (234-343), CH3 (344-448), CHS (449-450)) (121-450)], (223-219')-disulfure avec la chaîne légère kappa (1'-219') [V-KAPPA humanisé (*Homo sapiens* IGKV1-39*01 (78.00%) -IGKJ1*01) [11.3.9] (1'-112') -*Homo sapiens* IGKC*01 (113'-219')]; dimère (229-229'':232-232'')-bisdisulfure; conjugué, sur 3 à 4 cystéinyl en moyenne, au monométhylauristatine E (MMAE), via un linker clivable de type maléimidocaproyl-valyl-citrullinyl-*p*-aminobenzyloxycarbonyl (mc-val-cit-PABC)

Pour la partie védotine, veuillez-vous référer au document "INN for pharmaceutical substances: Names for radicals, groups and others".

lifastuzumab vedotina

immunoglobulina G1-kappa conjugada con la auristatina E, anti-[*Homo sapiens* SLC34A2 (miembro 2 de la familia 34 sodio fosfato de transportadores de solutos, cotransportador 2B de sodio/fosfato, NaPi2b, NaPi3b)], anticuerpo monoclonal humanizado conjugado con auristatina E; cadena pesada gamma1 (1-450) [VH humanizada (*Homo sapiens* IGHV3-23*04 (85.70%) -(IGHD)-IGHJ5*01) [8.8.13] (1-120) -*Homo sapiens* IGHG1*03 (CH1 R120>K (217) (121-218), bisagra (219-233), CH2 (234-343), CH3 (344-448), CHS (449-450)) (121-450)], (223-219')-disulfuro con la cadena ligera kappa (1'-219') [V-KAPPA humanizado (*Homo sapiens* IGKV1-39*01 (78.00%) -IGKJ1*01) [11.3.9] (1'-112') -*Homo sapiens* IGKC*01 (113'-219')]; dímero (229-229'':232-232'')-bisdisulfuro; conjugado, en una media de 3 a 4 restos cisteinil, con monometilauristatina E (MMAE), mediante un conector separable de tipo maleimidocaproyl-valil-citrulinil-*p*-aminobenciloxicarbonilo (mc-val-cit-PABC)

Para la fracción vedotina pueden referirse al documento "INN for pharmaceutical substances: Names for radicals, groups and others".

Heavy chain / Chaîne lourde / Cadena pesada
 EVQLVESGGG LVQPFGSLRL SCAASGFSPS DFAMSWVRQA PGKGLEWVAT 50
 IGRVAHTYY PDSMKGRFTI SRDSKNTLY LQMSLRAED TAVYYCARHR 100
 GFDVGHFDWF QGGTLTVSS ASTKGPSVFP LAPSSKSTSG GTAALGCLVK 150
 DYFPEPTVS WNSGALTSGV HTFFAVLQSS GLYSLSSVVT VPSSSLGTQT 200
 YICNVNHKPS NTKVDKKVEP KSCDKHTCTP PCPAPELLGG PSVFLFPPKP 250
 KDTLMISRTP EVTCVVVDVS HEDPEVKFNW YVDGVEVHNA KTKPREEQYN 300
 STYRVVSVLT VLHQDWLNGK EYCKVSNKA LPAPIEKTIS KAKGQPREPQ 350
 VYTLPPSREE MTRNQVSLTC LVKGFYPSDI AVEWESNGQP ENNYKTTTPV 400
 LQSDGSFFLY SKLTVDKSRW QQGNVFSCSV MHEALHNYT QKSLSLSPGK 450

Light chain / Chaîne légère / Cadena ligera
 DIQMTQSPSS LSASVGRDVT ITCRSSETLV HSGNTYLEW YQKPKGKAPK 50
 LLIYRVSNRF SGVPSRFSGS GSGTDFTLT ISSLQPEDFAT YYCFQGSFNP 100
 LTFGQGTKEV IKRTVAAPSV FIFPPSDEQL KSGTASVVC LNNFYFREAK 150
 VQWKVDNALQ SGNSQESVTE QDSKDYSL SSSLTSLSKAD YEKHKVYACE 200
 VTHQGLSSPV TKSFNRGEC 219

Disulfide bridges location / Position des ponts disulfure / Posiciones de los puentes disulfuro
 Intra-H (C23-C104) 22°-96° 147°-203° 264°-324° 370°-428°
 Intra-L (C23-C104) 23°-93° 139°-199°
 Inter-H-L (h 5-CL 126) * 223°-219° 223°-219°
 Inter-H-H (h 11, h 14) * 229°-229° 232°-232°

*Two or three of the inter-chain disulfide bridges are not present, an average of 3 to 4 cysteinyl being conjugated each via a thioether bond to a drug linker.
 *Deux ou trois des ponts disulfures inter-chaînes ne sont pas présents, 3 à 4 cystéinyl en moyenne étant chacun conjugué via une liaison thioéther à un linker-principe actif.
 *Faltan dos o tres puentes disulfuro inter-catenarios, una media de 3 a 4 cisteinil está conjugada a conectores de principio activo.

N-glycosylation sites / Sites de N-glycosylation / Posiciones de N-glicosilación
 H CH2 N84.4:
 300, 300"

lotilanerum

lotilaner


3-methyl-*N*-(2-oxo-2-[(2,2,2-trifluoroethyl)amino]ethyl)-5-[(5S)-5-(3,4,5-trichlorophenyl)-5-(trifluoromethyl)-4,5-dihydro-1,2-oxazol-3-yl]thiophene-2-carboxamide

lotilaner

3-méthyl-*N*-(2-oxo-2-[(2,2,2-trifluoroéthyl)amino]éthyl)-5-[(5S)-5-(3,4,5-trichlorophényl)-5-(trifluorométhyl)-4,5-dihydro-1,2-oxazol-3-yl]thiophène-2-carboxamide

lotilaner

3-metil-*N*-(2-oxo-2-[(2,2,2-trifluoroetil)amino]etil)-5-[(5S)-5-(3,4,5-triclorofenil)-5-(trifluorometil)-4,5-dihidro-1,2-oxazol-3-il]tiofeno-2-carboxamida

C₂₀H₁₄Cl₃F₆N₃O₃S**lubabegronum**

lubabegron


2-{4-[2-((2S)-2-hydroxy-3-[2-(thiophen-2-yl)phenoxy]propyl)amino)-2-methylpropyl]phenoxy}pyridine-3-carbonitrile

lubabégron

2-{4-[2-((2S)-2-hydroxy-3-[2-(thiophén-2-yl)phénoxy]propyl)amino)-2-méthylpropyl]phénoxy}pyridine-3-carbonitrile

lubabegrón

2-{4-[2-((2S)-2-hidroxi-3-[2-(tiofen-2-il)fenoxi]propil)amino)-2-metilpropil]fenoxi}piridina-3-carbonitrilo

C₂₉H₂₉N₃O₃S

lusaterceptum #
lusatercept

fusion protein for immune applications (FPIA) comprising the *Homo sapiens* ACVR2B (activin receptor type 2B, activin A receptor type IIB, activin receptor type IIB, ACTR-IIB, ActR-IIB) extracellular domain, fused with *Homo sapiens* immunoglobulin G1 Fc fragment; *Homo sapiens* ACVR2B precursor fragment 25-131 L79>D (55) (1-107) -linker triglycyl (108-110) -gamma1 chain H-CH2-CH3 fragment [*Homo sapiens* IGHG1*03 (hinge 8-15 (111-118), CH2 (119-228), CH3 (229-333), CHS (334-335))] (111-335); dimer (114-114':117-117')-bisdisulfide

lusatercept

protéine de fusion pour applications immunitaires (FPIA) comprenant le domaine extracellulaire d'*Homo sapiens* ACVR2B (récepteur de type 2B de l'activine, récepteur de type IIB de l'activine A, récepteur de type IIB de l'activine, ACTR-IIB, ActR-IIB), fusionné au fragment Fc de l'*Homo sapiens* immunoglobuline G1; *Homo sapiens* ACVR2B fragment 25-131 du précurseur L79>D (55) (1-107) -linker triglycyl (108-110) -fragment H-CH2-CH3 de la chaîne gamma1 [*Homo sapiens* IGHG1*03 (charnière 8-15 (111-118), CH2 (119-228), CH3 (229-333), CHS (334-335))] (111-335); dimère (114-114':117-117')-bisdisulfure

lusatercept

proteína de fusión para aplicaciones inmunitarias (FPIA) que comprende el dominio extracelular d'*Homo sapiens* ACVR2B (receptor de tipo 2B de la activina, receptor de tipo IIB de la activina A, receptor de tipo IIB de la activina, ACTR-IIB, ActR-IIB), fusionada con el fragmento Fc de la inmunoglobulina G1 de *Homo sapiens*; *Homo sapiens* ACVR2B fragmento 25-131 del precursor L79>D (55) (1-107) -linker triglicil (108-110) -fragmento H-CH2-CH3 de la cadena gamma1 [*Homo sapiens* IGHG1*03 (bisagra 8-15 (111-118), CH2 (119-228), CH3 (229-333), CHS (334-335))] (111-335); dímero (114-114':117-117')-bisdisulfuro

Fused chain / chaîne fusionnée / cadena fusionada

```
ETRECIYYNA NWELERTNQS GLERCEGEQD KRLHCYASWR NSSGTIELVK 50
KGCWDDDFNC YDRQECVATE ENPQVVFCCC EGNFCNERFT HLPBAGGPEV 100
TYEPPPTGGG THTCPPCPAP ELLGGPSVFL FPPKPKDTLM ISRTPEVTCV 150
VVDVSHEDPE VKFNWYVDGV EVHNAKTKPR EEQYNSTYRV VSVLTVLHQD 200
WLNKEYKCK VSNKALPAPI EKTISKAKGQ PREPQVYTLF PSREEMTKNQ 250
VSLTCLVKGF YPSDIAVEWE SNGQPENNYK TTPPVLDSDG SFPLYSKLTV 300
DKSRWQQGNV FSCSVMEAL HNHYTKSLS LSPGK 335
```

Disulfide bridges location / Position des ponts disulfure / Posiciones de los puentes disulfuro

```
Intrachain ACVR2B 5-35 25-53 60-79 66-78 80-85
IGHG1 (C23-C104) 5'-35' 25'-53' 60'-79' 66'-78' 80'-85'
IGHG1 (C23-C104) 149-209 255-313
149'-209' 255'-313'
```

Interchain IGHG1 (h 11, h 14) 114-114' 117-117'

N-glycosylation sites / Sites de N-glycosylation / Posiciones de N-glicosilación

ACVR2B:
18, 41, 18', 41'
IGHG1 CH2 N84.4:
185, 185'

mipsagarginum

mipsagargin

sarcoplasmic/endoplasmic reticulum Ca^{2+} dependent ATPase (SERCA) inhibitor conjugated to a peptide targeting prostate-specific membrane antigen (PSMA):


N^4 -(12-([(3S,3aR,4S,6S,6aR,7S,8S,9bS)-6-(acetyloxy)-3,3a-dihydroxy-3,6,9-trimethyl-8-([(2Z)-2-methylbut-2-enoyl]oxy)-7-(octanoyloxy)-2-oxo-2,3,3a,4,5,6,6a,7,8,9b-decahydroazuleno[4,5-b]furan-4-yl]oxy)-12-oxododecyl)-L-asparaginy-L- γ -glutamyl-L- γ -glutamyl-L- γ -glutamyl-L-glutamic acid

mipsagargine

inhibiteur de l'ATPase dépendante du Ca^{2+} du réticulum sarcoplasmique/endoplasmique conjugué à un peptide ciblant l'antigène prostatique membranaire spécifique (APMS):
acide N^4 -(12-([(3S,3aR,4S,6S,6aR,7S,8S,9bS)-6-(acétyloxy)-3,3a-dihydroxy-3,6,9-triméthyl-8-([(2Z)-2-méthylbut-2-énoyl]oxy)-7-(octanoyloxy)-2-oxo-2,3,3a,4,5,6,6a,7,8,9b-décahydroazuleno[4,5-b]furan-4-yl]oxy)-12-oxododécyl)-L-asparaginy-L- γ -glutamyl-L- γ -glutamyl-L- γ -glutamyl-L-glutamique

mipsagargina

inhibidor de la ATPasa dependiente de Ca^{2+} de retículo endoplásmico/sarcoplásmico (SERCA) conjugado con un péptido cuya diana es el antígeno de membrana específico de la próstata (PSMA):
ácido N^4 -(12-([(3S,3aR,4S,6S,6aR,7S,8S,9bS)-6-(acetiloxi)-3,3a-dihidroxi-3,6,9-trimetil-8-([(2Z)-2-metilbut-2-enoil]oxi)-7-(octanoiloxi)-2-oxo-2,3,3a,4,5,6,6a,7,8,9b-decahidroazuleno[4,5-b]furan-4-il]oxi)-12-oxododecil)-L-asparaginil-L- γ -glutamil-L- γ -glutamil-L- γ -glutamil-L-glutámico

 $\text{C}_{66}\text{H}_{100}\text{N}_6\text{O}_{27}$ **modotuximabum #**

modotuximab

immunoglobulin G1-kappa, anti-[*Homo sapiens* EGFR (epidermal growth factor receptor, ERBB1, HER1) domain III], chimeric monoclonal antibody;
gamma1 heavy chain (1-448) [*Mus musculus* VH (IGHV1S81*02 - (IGHD)-IGHJ4*01) [8.8.12] (1-119) -*Homo sapiens* IGHG1*03 CHS K2>del (120-448)], (222-219')-disulfide with kappa light chain (1'-219') [*Mus musculus* V-KAPPA (IGKV2-109*01 -IGKJ2*01) [11.3.9] (1'-112') -*Homo sapiens* IGKC*01 (113'-219')]; (228-228'':231-231'')-bisdisulfide dimer

modotuximab	immunoglobuline G1-kappa, anti-[<i>Homo sapiens</i> EGFR (récepteur du facteur de croissance épidermique ERBB1, HER1) domaine III], anticorps monoclonal chimérique; chaîne lourde gamma1 (1-448) [<i>Mus musculus</i> VH (IGHV1S81*02 - (IGHD)-IGHJ4*01) [8.8.12] (1-119) - <i>Homo sapiens</i> IGHG1*03 CHS K2>del (120-448)], (222-219')-disulfure avec la chaîne légère kappa (1'-219') [<i>Mus musculus</i> V-KAPPA (IGKV2-109*01 -IGKJ2*01) [11.3.9] (1'-112') - <i>Homo sapiens</i> IGKC*01 (113'-219')]; dimère (228-228":231-231")-bisdisulfure
modotuximab	immunoglobulina G1-kappa, anti-[EGFR de <i>Homo sapiens</i> (receptor del factor de crecimiento epidérmico ERBB1, HER1) dominio III], anticuerpo monoclonal quimérico; cadena ligera gamma1 (1-448) [<i>Mus musculus</i> VH (IGHV1S81*02 - (IGHD)-IGHJ4*01) [8.8.12] (1-119) - <i>Homo sapiens</i> IGHG1*03 CHS K2>del (120-448)], (222-219')-disulfuro con la cadena ligera kappa (1'-219') [<i>Mus musculus</i> V-KAPPA (IGKV2-109*01 -IGKJ2*01) [11.3.9] (1'-112') - <i>Homo sapiens</i> IGKC*01 (113'-219')]; dímero (228-228":231-231")-bisdisulfuro Heavy chain / Chaîne lourde / Cadena pesada QVQLQQPGAE LVEPGGSVKL SCKASGYTFT SHWMHWVKQR PGQGLEWIGE 50 INPSSGRNNY NEFKFSKATL TVDKSSSTAY MQFSSLTSED SAVYYCVRY Y 100 GYDEAMDYWG QGTSVTVSSA STKGPSVFPL APSSKSTSGG TAALGCLVKD 150 YFPEPVTVSW NSGALTSGVH TFPAYLQSSG LYSLSVTVT PSSSLGTQTY 200 ICNVNHHPSN TKVDKRVEPK SCDKTHTCPP CPAPELLGGP SVFLFPPKPK 250 DTLMISRTEF VTCVVDVDSH EDPEVKFNWY VDGVEVHNAK TKPREEQYNS 300 TYRVVSVLTV LHQDWLNGKE YKCKVSNKAL PAPIEKTISK AKGQPREPQV 350 YTLPPSREEM TKNQVSLTCL VKGFYPSDIA VEWESNGQPE NNYKTTTPVL 400 DSDGSFFLYS KLTVDKSRWQ QGNVFSCVM HEALHNHYTQ KSLSLSPG 448 Light chain / Chaîne légère / Cadena ligera DIVMTQAAFS NPVTLTGSAS ISCRSSKSL L HSNGITLYLW YLQKPGQSPQ 50 LLIYQMSNLA SGVPDRFSSS GSGTDFTLRI SRVEAEVGV YYCAQNLLELP 100 YTFGGGTKLE IKRTVAAPSV FIFPPSDEQL KSGTASVCL LNNEYPREAK 150 VQWKVDNALQ SGNSQESVTE QDSKSTYSL SSTLTLSKAD YEKHKVYACE 200 VTHQGLSSPV TKSFNREGC 219 Disulfide bridges location / Position des ponts disulfure / Posiciones de los puentes disulfuro Intra-H 22-96 146-202 263-323 369-427 22"-96" 146"-202" 263"-323" 369"-427" Intra-L 23-93 139-199" 23"-93" 139"-199" Inter-H-L 222-219' 222"-219" Inter-H-H 228-228" 231-231" N-glycosylation sites / Sites de N-glycosylation / Posiciones de N-glicosilación H CH2 N84.4: 299, 299"
osilodrostatum	
osilodrostat	4-[(5 <i>R</i>)-6,7-dihydro-5 <i>H</i> -pyrrolo[1,2- <i>c</i>]imidazol-5-yl]-3-fluorobenzonitrile
osilodrostat	4-[(5 <i>R</i>)-6,7-dihydro-5 <i>H</i> -pyrrolo[1,2- <i>c</i>]imidazol-5-yl]-3-fluorobenzonitrile
osilodrostat	4-[(5 <i>R</i>)-6,7-dihydro-5 <i>H</i> -pirrolo[1,2- <i>c</i>]imidazol-5-il]-3-fluorobenzonitrilo C ₁₃ H ₁₀ FN ₃

otlertuzumabum #
otlertuzumab

immunoglobulin G1-kappa heavy chain dimer, anti-[*Homo sapiens* CD37 (tetraspanin-26, TSPAN26)], humanized monoclonal antibody; gamma1-kappa heavy chain 'VH-linker-V-KAPPA-hinge-CH2-CH3' (1-483) [humanized VH (*Homo sapiens* IGHV5-51*01 (84.70%) - (IGHD)-IGHJ5*01) [8.8.9] (1-116) -linker pentakis(tetraglycyl-seryl) (117-141) -humanized V-KAPPA (*Homo sapiens* IGKV3-NL2 (89.90%) -IGKJ1*01) [6.3.9] (142-248) -linker glycyl-aspartyl-glutaminy (249-251) -*Homo sapiens* IGHG1*01 (hinge C5>S (256), C11>S (262) (252-266), CH2 (267-376), CH3 (377-481), CHS (482-483)) (252-483)]; dimer (265-265')-disulfide

otlertuzumab

immunoglobuline G1-kappa chaîne lourde dimère, anti-[*Homo sapiens* CD37 (tétraspanine-26, TSPAN26)], anticorps monoclonal humanisé; gamma1-kappa chaîne lourde 'VH-linker-V-KAPPA-charnière-CH2-CH3' (1-483) [VH humanisé (*Homo sapiens* IGHV5-51*01 (84.70%) - (IGHD)-IGHJ5*01) [8.8.9] (1-116) -linker pentakis(tétraglycyl-séryl) (117-141) -V-KAPPA humanisé (*Homo sapiens* IGKV3-NL2 (89.90%) -IGKJ1*01) [6.3.9] (142-248) -linker glycyl-aspartyl-glutaminy (249-251) -*Homo sapiens* IGHG1*01 (charnière C5>S (256), C11>S (262) (252-266), CH2 (267-376), CH3 (377-481), CHS (482-483)) (252-483)]; dimère (265-265')-disulfure

otlertuzumab

immunoglobulina G1-kappa cadena pesada dímero, anti-[*Homo sapiens* CD37 (tetraspanina-26, TSPAN26)], anticuerpo monoclonal humanizado; gamma1-kappa cadena pesada 'VH-linker-V-KAPPA-bisagra-CH2-CH3' (1-483) [VH humanizado (*Homo sapiens* IGHV5-51*01 (84.70%) - (IGHD)-IGHJ5*01) [8.8.9] (1-116) -linker pentakis(tetraglicil-seril) (117-141) -V-KAPPA humanizado (*Homo sapiens* IGKV3-NL2 (89.90%) -IGKJ1*01) [6.3.9] (142-248) -linker glicil-aspartil-glutaminil (249-251) -*Homo sapiens* IGHG1*01 (bisagraC5>S (256), C11>S (262) (252-266), CH2 (267-376), CH3 (377-481), CHS (482-483)) (252-483)]; dímero (265-265')-disulfuro

Heavy chain / Chaîne lourde / Cadena pesada

EVQLVQSGAE	VKKFGESLKI	SCKGSGYSFT	GYNMNVVRQM	PGKGLEWMGN	50
IDPYYGGTTY	NRKFKGQVTI	SADKSISTAY	LQWSSLKASD	TAMYCARSV	100
GPFDSWGQGT	LVTVSSGGGG	SGGGSGGGGG	SGGGSGGGGG	SEIVLTQSPA	150
TLSLSPGERA	TLSCRASENV	YSYLAWYQQK	PGQAPRLLIY	FAKTLAEGIP	200
ARFSGSGSGT	DFTLTISSE	PEDFAVYQC	HSDNPWTFG	QGTKEIKGD	250
QEPKSSDKTH	TSPPCPAPEL	LGGPVSFLFP	PKPKDTLMIS	RTPEVTCVVV	300
DVSHEDPEVK	FNWYVDGVEV	HNAKTKPREE	QYNSTYRVVS	VLTVLHQDWL	350
NGKEYKCKVS	NKALPAPIEK	TISKAKGQPR	EPQVYTLPPS	RDELTKNQVS	400
LTCLVKGFYP	SDIAVEWESN	GQPENNYKTT	PPVLDSDGSF	FLYSKLTVDK	450
SRWQQGNVFS	CSVMHEALHN	HYTQKSLSL	SGK		483

Disulfide bridges location / Position des ponts disulfure / Posiciones de los puentes disulfuro

Intra-H (C23-C104)	22-96	164-229	297-357	403-461
	22"-96"	164"-229"	297"-357"	403"-461"
Inter-H-H (h 14)	265-265'			

N-glycosylation sites / Sites de N-glycosylation / Posiciones de N-glicosilación

H CH2 N84.4:
333, 333"

pembrolizumabum #

pembrolizumab

immunoglobulin G4-kappa, anti-[*Homo sapiens* PDCD1 (programmed cell death 1, PD-1, PD1, CD279)], humanized monoclonal antibody;
gamma4 heavy chain (1-447) [humanized VH (*Homo sapiens*IGHV1-2*02 (79.60%) -(IGHD)-IGHJ4*01 L123>T (115)) [8.8.13] (1-120) -*Homo sapiens* IGHG4*01 (CH1 (121-218), hinge S10>P (228) (219-230), CH2 (231-340), CH3 (341-445), CHS (446-447)) (121-447)], (134-218')-disulfide with kappa light chain (1'-218') [humanized V-KAPPA (*Homo sapiens* IGKV3D-11*01 (85.10%) -IGKJ4*01) [10.3.9] (1'-111') -*Homo sapiens* IGKC*01 (112'-218')]; dimer (226-226":229-229")-bisdisulfide

pembrolizumab

immunoglobuline G4-kappa, anti-[*Homo sapiens* PDCD1 (protéine 1 de mort cellulaire programmée, PD-1, PD1, CD279)], anticorps monoclonal humanisé;
chaîne lourde gamma4 (1-447) [VH humanisé (*Homo sapiens*IGHV1-2*02 (79.60%) -(IGHD)-IGHJ4*01 L123>T (115)) [8.8.13] (1-120) -*Homo sapiens* IGHG4*01 (CH1 (121-218), charnière S10>P (228) (219-230), CH2 (231-340), CH3 (341-445), CHS (446-447)) (121-447)], (134-218')-disulfure avec la chaîne légère kappa (1'-218') [V-KAPPA humanisé (*Homo sapiens* IGKV3D-11*01 (85.10%) -IGKJ4*01) [10.3.9] (1'-111') -*Homo sapiens* IGKC*01 (112'-218')]; dimère (226-226":229-229")-bisdisulfure

pembrolizumab

inmunoglobulina G4-kappa, anti-[PDCD1 de *Homo sapiens* (proteína 1 de muerte celular programada, PD-1, PD1, CD279)], anticuerpo monoclonal humanizado;
cadena pesada gamma4 (1-447) [VH humanizado (*Homo sapiens*IGHV1-2*02 (79.60%) -(IGHD)-IGHJ4*01 L123>T (115)) [8.8.13] (1-120) -*Homo sapiens* IGHG4*01 (CH1 (121-218), bisagra S10>P (228) (219-230), CH2 (231-340), CH3 (341-445), CHS (446-447)) (121-447)], (134-218')-disulfuro con la cadena ligera kappa (1'-218') [V-KAPPA humanizado (*Homo sapiens* IGKV3D-11*01 (85.10%) -IGKJ4*01) [10.3.9] (1'-111') -*Homo sapiens* IGKC*01 (112'-218')]; dímero (226-226":229-229")-bisdisulfuro

Heavy chain / Chaîne lourde / Cadena pesada
QVQLVQSGVE VKKPGASVKV SCASGYTFT NYMYWVRQA PGQGLEWMGG 50
INPSNGGTNF NEKFKNRYTL TDSSTTTAY MELKSLQFDD TAVVYCARRD 100
YRFDMGFDYV GQGTITVTSS ASTKGPSVFP LAPCSRSTSE STAALGCLVK 150
DYFPEPVTVS WNSGALTSGV HTFPAVLQSS GLYSLSVVVT VPSSSLGKTK 200
YTCNVDPKPS NTKVDKRVES KYGPCCPCCP APEFLGGPSV FLFPKPKKDT 250
LMISRTPEVT CVVVDVSQED FEVQFNWYVD GVEVHNATK PREEQFNSTY 300
RVVSVLTVLH QDWLNGKEYK CKVSNKGLPS SIEKTISKAK GQPREPQVYT 350
LPFSSQEMTK NQVSLTCLVK GFYPSDIAVE WESNGQPENN YKTPFPVLD 400
DGSFFLYSRL TVDKSRWQEG NVFSCSVMEH ALHNHYTQKS LSLSLGK 447

Light chain / Chaîne légère / Cadena ligera
EIVLTQSPAT LSLSPGERAT LSCRASKGVS TSGYSYLHWY QKQPGQAPRL 50
LIYLAAYLES GVPARFSGSG SGTDFLTIS SLEPEDFAVY YCQHSRDLPL 100
TFGGGTKVEI KRTVAAPSVF IFPPSDEQLK SGTASVCLL NNFYPREAKV 150
QWKVDNALQS GNSQESVTEQ DSKDSTYSLT STLTLKADY EKHKVYACEV 200
THQGLSSPVT KSFNRGEC 218

Disulfide bridges location / Position des ponts disulfure / Posiciones de los puentes disulfuro

Intra-H (C23-C104) 22-96 147-203 261-321 367-425
22"-96" 147"-203" 261"-321" 367"-425"

Intra-L (C23-C104) 23'-92' 138"-198"
23'''-92''' 138'''-198'''

Inter-H-L (CH1 10-CL 126) 134-218' 134"-218"
Inter-H-H (h 8, h 11) 226-226" 229-229"

N-glycosylation sites / Sites de N-glycosylation / Posiciones de N-glicosilación

H CH2 N84.4:
297, 297"

pexmetinibum

pexmetinib


N-[3-*tert*-butyl-1-(4-methylphenyl)-1*H*-pyrazol-5-yl]-*N*'-[(5-fluoro-2-[[1-(2-hydroxyethyl)-1*H*-indazol-5-yl]oxy]phenyl)methyl]urea

pexméтиниб

N-[3-*tert*-butyl-1-(4-méthylphényl)-1*H*-pyrazol-5-yl]-*N'*-[(5-fluoro-2-[[1-(2-hydroxyéthyl)-1*H*-indazol-5-yl]oxy]phényl)méthyl]urée

pexmetinib

N-[3-*tert*-butyl-1-(4-méthylphényl)-1*H*-pyrazol-5-yl]-*N'*-[(5-fluoro-2-[[1-(2-hydroxyéthyl)-1*H*-indazol-5-yl]oxy]phényl)méthyl]urée

C₃₁H₃₃FN₆O₃

pretomanidum

pretomanid


(6*S*)-2-nitro-6-[[4-(trifluorométhoxy)phényl]méthoxy]-6,7-dihydro-5*H*-imidazo[2,1-*b*][1,3]oxazine

prétomanid

(6*S*)-2-nitro-6-[[4-(trifluorométhoxy)phényl]méthoxy]-6,7-dihydro-5*H*-imidazo[2,1-*b*][1,3]oxazine

pretomanid

(6*S*)-2-nitro-6-[[4-(trifluorométhoxy)phényl]méthoxy]-6,7-dihydro-5*H*-imidazo[2,1-*b*][1,3]oxazine


C₁₄H₁₂F₃N₃O₅

ralpancizumabum #

ralpancizumab

immunoglobulin G2-kappa, anti-[*Homo sapiens* PCSK9 (proprotein convertase subtilisin/kexin type 9, neural apoptosis-regulated convertase 1, NARC1, NARC-1, proprotein convertase 9, PC9)], humanized monoclonal antibody; gamma2 heavy chain (1-444) [humanized VH (*Homo sapiens*IGHV1-46*01 (91.80%) -(IGHD)-IGHJ1*01 L123>T (113)) [8.8.11] (1-118) -*Homo sapiens*IGHG2*01 (CH1 (119-216), hinge (217-228), CH2 A115>S (327), P116>S (328) (229-337), CH3 (338-442), CHS (443-444)) (119-444)], (132-214')-disulfide with kappa light chain (1'-214') [humanized V-KAPPA (*Homo sapiens*IGKV1-33*01 (85.10%) -IGKJ2*01 [6.3.9] (1'-107') -*Homo sapiens*IGKC*01 (108'-214'))]; dimer (220-220":221-221":224-224":227-227")-tetrakisdisulfide

ralpancizumab	immunoglobuline G2-kappa, anti-[<i>Homo sapiens</i> PCSK9 (proprotéine convertase subtilisine/kexine type 9, convertase 1 régulée par l'apoptose neuronale, NARC1, NARC-1, proprotéine convertase 9, PC9)], anticorps monoclonal humanisé; chaîne lourde gamma2 (1-444) [VH humanisé (<i>Homo sapiens</i> IGHV1-46*01 (91.80%) -(IGHD)-IGHJ1*01 L123>T (113)) [8.8.11] (1-118) - <i>Homo sapiens</i> IGHG2*01 (CH1 (119-216), charnière (217-228), CH2 A115>S (327), P116>S (328) (229-337), CH3 (338-442), CHS (443-444)) (119-444)], (132-214')-disulfure avec la chaîne légère kappa (1'-214') [V-KAPPA humanisé (<i>Homo sapiens</i> IGKV1-33*01 (85.10%) -IGKJ2*01) [6.3.9] (1'-107') - <i>Homo sapiens</i> IGKC*01 (108'-214')]; dimère (220-220":221-221":224-224":227-227")-tétrakisdisulfure
ralpancizumab	immunoglobulina G2-kappa, anti-[<i>Homo sapiens</i> PCSK9 (proteína convertasa subtilisina/kexina tipo 9, convertasa 1 regulada por la apoptosis neuronal, NARC1, NARC-1, proteína convertasa 9, PC9)], anticuerpo monoclonal humanizado; cadena pesada gamma2 (1-444) [VH humanizado (<i>Homo sapiens</i> IGHV1-46*01 (91.80%) -(IGHD)-IGHJ1*01 L123>T (113)) [8.8.11] (1-118) - <i>Homo sapiens</i> IGHG2*01 (CH1 (119-216), bisagra (217-228), CH2 A115>S (327), P116>S (328) (229-337), CH3 (338-442), CHS (443-444)) (119-444)], (132-214')-disulfuro con la cadena ligera kappa (1'-214') [V-KAPPA humanizado (<i>Homo sapiens</i> IGKV1-33*01 (85.10%) -IGKJ2*01) [6.3.9] (1'-107') - <i>Homo sapiens</i> IGKC*01 (108'-214')]; dímero (220-220":221-221":224-224":227-227")-tatrakidisulfuro
	Heavy chain / Chaîne lourde / Cadena pesada QVQLVQSGAE VKKPGASVKV SCKASGYTFT SYMHWRQA PGQGLEWMGE 50 IHPSGGRTNY NEKFKSRVTM TRDTSSTVY MELSSLRSED TAVYYCARER 100 PLYASDLWGQ GTTIVTSSAS TKGPSVFPLA PCSRSTSEST AALGCLVKDY 150 FPEPVTVSWN SGALTSGVHT FPAVLQSSGL YSLSSVTVTP SSNFGTQTYT 200 CNVDHKPSNT KVDKTVERKC CVECPCPCAP PVAGPSVFLF PPKPKDTLMI 250 SRTPEVTCVV VDVSHEDPEV QFNWYVDGVE VHNATKPRE EQFNSTFRVV 300 SVLTIVVHQDW LNKKEYKCKV SNKGLPSSIE KTISKTKGQP REPQVYTLFP 350 SREEMTKNQV SLTCLVKGfy PSDIAVEWES NGQPENNYKT TFPMLDSGDS 400 FFLYSKLTVD KSRWQQGNVF SCSVMHEALH NHYTQKSLSL SPGK 444 Light chain / Chaîne légère / Cadena ligera DIQMTQSPSS LSASVGRVT ITCKASQDVH TAVAWYQQKPKAPKLLIYH 50 ASYRYTGVPF RFGSGSGSTD FTFTISLQP EDIATYYCQ RYSLWRTFGQ 100 GTKLEIKRTV AAPSVFIFPP SDEQLKSGTA SVVCLNNFY PREAKVQWQV 150 DNALQSGNSQ ESVTEQDSKD STYSLSTLT LSKADYEKHK VYACEVTHQG 200 LSSPVTKSFN RGEK 214 Disulfide bridges location / Position des ponts disulfure / Posiciones de los puentes disulfuro Intra-H (C23-C104) 22-96 145-201 258-318 364-422 22"-96" 145"-201" 258"-318" 364"-422" Intra-L (C23-C104) 23'-88' 134'-194' 23'''-88''' 134'''-194''' Inter-H-L (CH1 10-CL 126) 132-214' 132"-214" Inter-H-H (h 4, h 5, h 11, h 14) 220-220" 221-221" 224-224" 227-227" N-glycosylation sites / Sites de N-glycosylation / Posiciones de N-glicosilación H CH2 N84.4: 294, 294"
relamorelinum	
relamorelin	[3-(1-benzothiophen-3-yl)- <i>N</i> -(piperidin-4-ylcarbonyl)-D-alanyl]-D-tryptophyl-L-phenylalanyl-(4-aminopiperidine-4-carboxamide)
relamoréline	[3-(1-benzothiophén-3-yl)- <i>N</i> -(pipéridin-4-ylcarbonyl)-D-alanyl]-D-tryptophyl-L-phénylalanyl-(4-aminopipéridine-4-carboxamide)
relamorelina	[3-(1-benzotiofen-3-il)- <i>N</i> -(piperidin-4-ilcarbonil)-D-alanil]-D-triptofil-L-fenilalanil-(4-aminopiperidina-4-carboxamida)

C₄₃H₅₀N₈O₅S

ribuvaptanum
ribuvaptan


(2*R*)-2-({3-(4-chlorophenyl)-5-oxo-4-[(2*S*)-3,3,3-trifluoro-2-hydroxypropyl]-4,5-dihydro-1*H*-1,2,4-triazol-1-yl}acetamido)-2-[3-(trifluoromethyl)phenyl]ethyl carbamate

ribuvaptan

carbamate de (2*R*)-2-({3-(4-chlorophényl)-5-oxo-4-[(2*S*)-3,3,3-trifluoro-2-hydroxypropyl]-4,5-dihydro-1*H*-1,2,4-triazol-1-yl}acétamido)-2-[3-(trifluorométhyl)phényl]éthyle

ribuvaptán

carbamato de (2*R*)-2-({3-(4-clorofenil)-5-oxo-4-[(2*S*)-3,3,3-trifluoro-2-hidroxiopropil]-4,5-dihidro-1*H*-1,2,4-triazol-1-il}acetamido)-2-[3-(trifluorometil)fenil]etilo

C₂₃H₂₀ClF₆N₅O₅

samatasvirum
samatasvir


methyl {(1*R*)-2-[(2*S*)-2-{4-[4-(6-{2-[(2*S*)-1-{(2*S*)-2-[(methoxycarbonyl)amino]-3-methylbutanoyl]pyrrolidin-2-yl]-1*H*-benzimidazol-5-yl}thieno[3,2-*b*]thien-3-yl)phenyl]-1*H*-imidazol-2-yl]pyrrolidin-1-yl]-2-oxo-1-phenylethyl}carbamate

samatasvir

{(1*R*)-2-[(2*S*)-2-{4-[4-(6-{2-[(2*S*)-1-{(2*S*)-2-[(méthoxycarbonyl)amino]-3-méthylbutanoyl]pyrrolidin-2-yl]-1*H*-benzimidazol-5-yl}thieno[3,2-*b*]thién-3-yl)phényl]-1*H*-imidazol-2-yl]pyrrolidin-1-yl]-2-oxo-1-phényléthyl}carbamate de méthyle

samatasvir

{(1*R*)-2-[(2*S*)-2-{4-[4-(6-{2-[(2*S*)-1-{(2*S*)-2-[(metoxycarbonyl)amino]-3-metilbutanoyl]pirrolidin-2-il]-1*H*-benzoimidazol-5-il}tieno[3,2-*b*]tien-3-il}fenil]-1*H*-imidazol-2-il]pirrolidin-1-il]-2-oxo-1-feniletíl}carbamato de metilo

C₄₇H₄₈N₈O₆S₂**selinexorum**


selinexor

(2*Z*)-3-[3-[3,5-bis(trifluoromethyl)phenyl]-1*H*-1,2,4-triazol-1-yl]-*N'*-(pyrazin-2-yl)prop-2-enehydrazide

sélinexor

(2*Z*)-3-[3-[3,5-bis(trifluorométhyl)phényl]-1*H*-1,2,4-triazol-1-yl]-*N'*-(pyrazin-2-yl)prop-2-ènehydrazide

selinexor

(2*Z*)-3-[3-[3,5-bis(trifluorometil)fenil]-1*H*-1,2,4-triazol-1-il]-*N'*-(pirazin-2-il)prop-2-enohidrazidaC₁₇H₁₁F₆N₇O**sepetaprostum**


sepetaprost

propan-2-yl 4-[(3*S*,5*aR*,6*R*,7*R*,8*aS*)-6-[(1*E*,3*R*)-4-(2,5-difluorophenoxy)-3-hydroxybut-1-en-1-yl]-7-hydroxyoctahydro-2*H*-cyclopenta[*b*]oxepin-3-yl]butanoate

sépetaprost

4-[(3*S*,5*aR*,6*R*,7*R*,8*aS*)-6-[(1*E*,3*R*)-4-(2,5-difluorophénoxy)-3-hydroxybut-1-én-1-yl]-7-hydroxyoctahydro-2*H*-cyclopenta[*b*]oxépin-3-yl]butanoate de propan-2-yle

sepetaprost

4-[(3*S*,5*aR*,6*R*,7*R*,8*aS*)-6-[(1*E*,3*R*)-4-(2,5-difluorofenoxi)-3-hidroxi-but-1-en-1-il]-7-hidroxi-octahidro-2*H*-ciclopenta[*b*]oxepin-3-il]butanoato de propan-2-iloC₂₆H₃₆F₂O₆

sofituzumabum vedotinum #
sofituzumab vedotin

immunoglobulin G1-kappa auristatin E conjugate, anti-[*Homo sapiens* MUC16 (mucin 16, MUC-16, cancer antigen 125, CA125)], humanized monoclonal antibody conjugated to auristatin E; gamma1 heavy chain (1-446) [humanized VH (*Homo sapiens*IGHV3-48*03 (79.80%) -(IGHD)-IGHJ4*01) [9.8.9] (1-116) -*Homo sapiens*IGHG1*03 (CH1 R120>K (213) (117-214), hinge (215-229), CH2 (230-339), CH3 (340-444), CHS (445-446)) (117-446)], (219-214')-disulfide with kappa light chain (1'-214') [humanized V-KAPPA (*Homo sapiens*IGKV1-5*01 (87.90%) -IGKJ1*01) [6.3.9] (1'-107') -*Homo sapiens*IGKC*01 (108'-214')]; dimer (225-225":228-228")-bisdisulfide; conjugated, on an average of 3 to 4 cysteinyl, to monomethylauristatin E (MMAE), via a cleavable maleimidocaproyl-valyl-citrullinyl-*p*-aminobenzoyloxycarbonyl (mc-val-cit-PABC) type linker

For the vedotin part, please refer to the document "INN for pharmaceutical substances: Names for radicals, groups and others".

sofituzumab védotine

immunoglobuline G1-kappa conjuguée à l'auristatine E, anti-[*Homo sapiens* MUC16 (mucine 16, MUC-16, antigène de cancer 125, CA125)], anticorps monoclonal humanisé conjugué à l'auristatine E; chaîne lourde gamma1 (1-446) [VH humanisé (*Homo sapiens*IGHV3-48*03 (79.80%) -(IGHD)-IGHJ4*01) [9.8.9] (1-116) -*Homo sapiens*IGHG1*03 (CH1 R120>K (213) (117-214), charnière (215-229), CH2 (230-339), CH3 (340-444), CHS (445-446)) (117-446)], (219-214')-disulfure avec la chaîne légère kappa (1'-214') [V-KAPPA humanisé (*Homo sapiens*IGKV1-5*01 (87.90%) -IGKJ1*01) [6.3.9] (1'-107') -*Homo sapiens*IGKC*01 (108'-214')]; dimère (225-225":228-228")-bisdisulfure; conjugué, sur 3 à 4 cystéinyl en moyenne, au monométhylauristatine E (MMAE), via un linker clivable de type maléimidocaproïl-valyl-citrullinyl-*p*-aminobenzoyloxycarbonyl (mc-val-cit-PABC)


Pour la partie védotine, veuillez-vous référer au document "INN for pharmaceutical substances: Names for radicals, groups and others".

sofituzumab vedotina

inmunoglobulina G1-kappa conjugada con la auristatina E, anti-[*Homo sapiens* MUC16 (mucina 16, MUC-16, antígeno de cáncer 125, CA125)], anticuerpo monoclonal humanizado conjugado con la auristatina E; cadena pesada gamma1 (1-446) [VH humanizado (*Homo sapiens*IGHV3-48*03 (79.80%) -(IGHD)-IGHJ4*01) [9.8.9] (1-116) -*Homo sapiens*IGHG1*03 (CH1 R120>K (213) (117-214), bisagra (215-229), CH2 (230-339), CH3 (340-444), CHS (445-446)) (117-446)], (219-214')-disulfuro con la cadena ligera kappa (1'-214') [V-KAPPA humanizada (*Homo sapiens*IGKV1-5*01 (87.90%) -IGKJ1*01) [6.3.9] (1'-107') -*Homo sapiens*IGKC*01 (108'-214')]; dímero (225-225":228-228")-bisdisulfuro; conjugado, en una media de 3 a 4 restos cisteinil, con monometilauristatina E (MMAE), mediante un conector separable de tipo maleimidocaproil-valil-citrulinil-*p*-aminobencilloxicarbonilo (mc-val-cit-PABC)

Para la fracción vedotina pueden referirse al documento "INN for pharmaceutical substances: Names for radicals, groups and others".

	Heavy chain / Chaîne lourde / Cadena pesada EVQLVESGGG LVQPGGSLRL SCAASGYSIT NDYAWNWRQ APGKGLEWVG 50 YISYSGYTTY NPSLKSRFTI SRDTSKNTLY LQMNSLRAED TAVYYCARWT 100 SGLDYWGQGT LVTSSASTK GPSVFPLAPS SKSTSGGTAA LGCLVKDYFP 150 EPVTVSWNSG ALTSGVHTFP AVLQSSGLYS LSSVVTVPSS SLGTQTYICN 200 VNHRKPSNTRV DKKVEPKSCD KHTCPCPCPA PELLGGPSVF LFPPKPKDTL 250 MISRTPVETC VVVDVSHEDP EVKFNWYVDG VEVHNAKTKP REEQYNSTYR 300 VVSVLTVLHQ DWLNGKEYKC KVSNKALPAP IEKTISKAKG QPREPQVYTL 350 PPSREEMTKN QVSLTCLVKG FYPSDIAVEW ESNQGPNENY KTFPPVLDSD 400 GSFFLYSKLT VDKSRWQQGN VFSCSVMHEA LHNHYTQKSL SLSPGK 446 Light chain / Chaîne légère / Cadena ligera DIQMTQSPSS LSASVGRVT ITCKASDLIH NWLAWYQQKP GKAPKLLIYG 50 ATSLETGVPS RFGSGSGGTD FTLTISSLQP EDFATYYCQQ YWTTPTFTFGQ 100 GTKVEIKRTV AAPSVFIFPP SDEQLKSGTA SVVCLLNFEY PREAKVQWKV 150 LNALQSGNSQ ESVTEQDSKD STYSLSTLT LSKADYEKHK VYACEVTHQG 200 LSSPVTKSFN RGEK 214 Disulfide bridges location / Position des ponts disulfure / Posiciones de los puentes disulfuro Intra-H (C23-C104) 22°-96" 143°-199" 260°-320" 366°-424" 22°-96" 143°-199" 260°-320" 366°-424" Intra-L (C23-C104) 23°-88" 134°-194" 23°-88" 134°-194" Inter-H-L (h 5-CL 126) * 219°-214" 219°-214" Inter-H-H (h 11, h 14) * 225°-225" 228°-228" *Two or three of the inter-chain disulfide bridges are not present, an average of 3 to 4 cysteinyl being conjugated each via a thioether bond to a drug linker. *Deux ou trois des ponts disulfures inter-chaînes ne sont pas présents, 3 à 4 cystéinyl en moyenne étant chacun conjugué via une liaison thioéther à un linker. *Faltan dos o tres puentes disulfuro inter-catenarios, una media de 3 a 4 cisteinil está conjugada a conectores de principio activo. N-glycosylation sites / Sites de N-glycosylation / Posiciones de N-glicosilación H CH2 N84.4: 296, 296°
sotagliflozinum	
sotagliflozin	methyl (5S)-5-C-[4-chloro-3-[(4-ethoxyphenyl)methyl]phenyl]-1-thio-β-L-xylopyranoside
sotagliflozine	(5S)-5-C-[4-chloro-3-[(4-éthoxyphényl)méthyl]phényl]-1-thio-β-L-xylopyranoside de méthyle
sotagliflozina	(5S)-5-C-[4-cloro-3-[(4-etoxifenil)metil]fenil]-1-tio-β-L-xilopiranosido de metilo
	C₂₁H₂₅ClO₅S
taladegibum	
taladegib	4-fluoro-N-methyl-N-{1-[4-(1-methyl-1H-pyrazol-5-yl)phthalazin-1-yl]piperidin-4-yl}-2-(trifluoromethyl)benzamide
taladégib	4-fluoro-N-méthyl-N-{1-[4-(1-méthyl-1H-pyrazol-5-yl)phtalazin-1-yl]pipéridin-4-yl}-2-(trifluorométhyl)benzamide
taladegib	4-fluoro-N-metil-N-{1-[4-(1-metil-1H-pirazol-5-il)ftalazin-1-il]piperidin-4-il}-2-(trifluorometil)benzamida

C₂₆H₂₄F₄N₆O

talazoparibum
talazoparib


(8*S*,9*R*)-5-fluoro-8-(4-fluorophenyl)-9-(1-méthyl-1*H*-1,2,4-triazol-5-yl)-2,7,8,9-tétrahydro-3*H*-pyrido[4,3,2-*de*]phthalazin-3-one

talazoparib

(8*S*,9*R*)-5-fluoro-8-(4-fluorophényl)-9-(1-méthyl-1*H*-1,2,4-triazol-5-yl)-2,7,8,9-tétrahydro-3*H*-pyrido[4,3,2-*de*]phthalazin-3-one

talazoparib

(8*S*,9*R*)-5-fluoro-8-(4-fluorofenil)-9-(1-metil-1*H*-1,2,4-triazol-5-il)-2,7,8,9-tétrahidro-3*H*-pirido[4,3,2-*de*]ftalazin-3-ona

C₁₉H₁₄F₂N₆O

tilapertinum
tilapertin


(4-((*R*)-phényl[3-(trifluorométhyl)phényl]méthyl)piperazin-1-yl)acetic acid

tilapertine

acide (4-((*R*)-phényl[3-(trifluorométhyl)phényl]méthyl)pipérazin-1-yl)acétique

tilapertina

ácido (4-((*R*)-fenil[3-(trifluorometil)fenil]metil}piperazin-1-il)acético

C₂₀H₂₁F₃N₂O₂

ulocuplumabum #
ulocuplumab

immunoglobulin G4-kappa, anti-[*Homo sapiens* CXCR4 (chemokine (C-X-C motif) receptor 4, fusin, stromal cell-derived factor 1 receptor, SDF-1 receptor, CXCL12 receptor, CD184)], human monoclonal antibody;
gamma4 heavy chain (1-451) [*Homo sapiens* VH (IGHV3-48*02 (96.90%) -(IGHD)-IGHJ6*01 [8.8.18] (1-125) -IGHG4*01 (CH1 (126-223), hinge S10>P (233) (224-235), CH2 (236-345), CH3 (346-450), CHS K2>del (451)) (126-451)), (139-214')-disulfide with kappa light chain (1'-214') [*Homo sapiens* (V-KAPPA (IGKV1D-16*01 (98.90%) -IGKJ1*01 [6.3.9] (1'-107') -IGKC*01 (108'-214'))]; dimer (231-231":234-234")-bisdisulfide

ulocuplumab

immunoglobuline G4-kappa, anti-[*Homo sapiens* CXCR4 (récepteur 4 de chimiokine (C-X-C motif), fusine, récepteur du facteur 1 dérivé des cellules stromales, récepteur du SDF-1, récepteur du CXCL12, CD184)], anticorps monoclonal humain;
chaîne lourde gamma4 (1-451) [*Homo sapiens* VH (IGHV3-48*02 (96.90%) -(IGHD)-IGHJ6*01 [8.8.18] (1-125) -IGHG4*01 (CH1 (126-223), charnière S10>P (233) (224-235), CH2 (236-345), CH3 (346-450), CHS K2>del (451)) (126-451)), (139-214')-disulfure avec la chaîne légère kappa (1'-214') [*Homo sapiens* (V-KAPPA (IGKV1D-16*01 (98.90%) -IGKJ1*01 [6.3.9] (1'-107') -IGKC*01 (108'-214'))]; dimère (231-231":234-234")-bisdisulfure

ulocuplumab

immunoglobulina G4-kappa, anti-[*Homo sapiens* CXCR4 (receptor 4 de quimiokina (C-X-C motif), fusina, receptor del factor 1 derivado de células estromales, receptor del SDF-1, receptor del CXCL12, CD184)], anticuerpo monoclonal humano;
cadena pesada gamma4 (1-451) [*Homo sapiens* VH (IGHV3-48*02 (96.90%) -(IGHD)-IGHJ6*01 [8.8.18] (1-125) -IGHG4*01 (CH1 (126-223), bisagra S10>P (233) (224-235), CH2 (236-345), CH3 (346-450), CHS K2>del (451)) (126-451)), (139-214')-disulfuro con la cadena ligera kappa (1'-214') [*Homo sapiens* (V-KAPPA (IGKV1D-16*01 (98.90%) -IGKJ1*01 [6.3.9] (1'-107') -IGKC*01 (108'-214'))]; dímero (231-231":234-234")-bisdisulfuro

Heavy chain / Chaîne lourde / Cadena pesada

```
EVQLVESGGG LVQPGGSLRL SCAAAGFTFS SYSMNWVRQA PGKGLEWVS 50
ISSRSRTIYY ADSVKGRFTI SRDNAKNSLY LQMNSLRDED TAVYYCARDY 100
GGQPPYYIYY GMDVWGQGTI VTVSSASTKG PSVFPLAPCS RSTSESTAAL 150
GCLVKDYFPE PVTVSWNSGA LTSGVHTFPA VLQSSGLYSL SSVVTPPSS 200
LGTKTYTICNV DHKPSNTKVD KRVESKYGPP CPFCPEPEFL GGPVSFVFP 250
KPKDTLMISR TPEVTCVVVD VSQEDPEVQF NWYVDGVEVH NAKTKPREEQ 300
FNSTYRVVSV LTVLHQDWLN GKEYKCKVSN KGLPSSIEKT ISKAKGQPRE 350
PQVYTLPPSQ EEMTKNQVSL TCLVKGFYPS DIAVEWESNG QPENNYKTP 400
PVLDSGDSFF LYSRLTVDKS RWQEGNVFSC SVMHEALHNN YTKRSLSLSL 450
G 451
```

Light chain / Chaîne légère / Cadena ligera

```
DIQMTQSPSS LSASVGDRVT ITCRASQGIS SWLAWYQQK EKAPKSLIYA 50
ASSLSQGVPS RFGSGSGTD FTLTISSLQ EDFTVYYCQ YNSYPRTFGQ 100
GTKVEIKRTV AAPSVFIFPP SDEQLKSGTA SVVCLLNIFY PRAKVVQWKV 150
DNALQSGNSQ ESVTEQDSKD STYSLSSLT LSKADYEKKH VYACEVTHQG 200
LSSPVTKSFN RGEC 214
```

Disulfide bridges location / Position des ponts disulfure / Posiciones de los puentes disulfuro

Intra-H (C23-C104) 22-96 152-208 266-326 372-430
22"-96" 152"-208" 266"-326" 372"-430"
Intra-L (C23-C104) 23'-88" 134'-194"
23'''-88''' 134'''-194'''
Inter-H-L (CH1 10-CL 126) 139-214' 139"-214"
Inter-H-H (h 8, h 11) 231-231" 234-234"

N-glycosylation sites / Sites de N-glycosylation / Posiciones de N-glicosilación
H CH2 N84.4:
302, 302"

veledimexum


veledimex

N'-(3,5-dimethylbenzoyl)-*N'*-[(3*R*)-2,2-dimethylhexan-3-yl]-2-ethyl-3-methoxybenzohydrazide

vélédimex

N'-(3,5-diméthylbenzoyl)-*N'*-[(3*R*)-2,2-diméthylhexan-3-yl]-2-éthyl-3-méthoxybenzohydrazide

veledimex

N'-(3,5-diméthilbenzoil)-*N'*-[(3*R*)-2,2-diméthilhexan-3-il]-2-etil-3-metoxibenzohidrazidaC₂₇H₃₈N₂O₃**verdinexorum**


verdinexor

(2*Z*)-3-[3-[3,5-bis(trifluoromethyl)phenyl]-1*H*-1,2,4-triazol-1-yl]-*N'*-(pyridin-2-yl)prop-2-enehydrazide

verdinexor

(2*Z*)-3-[3-[3,5-bis(trifluorométhyl)phényl]-1*H*-1,2,4-triazol-1-yl]-*N'*-(pyridin-2-yl)prop-2-ènehydrazide

verdinexor

(2*Z*)-3-[3-[3,5-bis(trifluorometil)fenil]-1*H*-1,2,4-triazol-1-il]-*N'*-(piridin-2-il)prop-2-enohidrazidaC₁₈H₁₂F₆N₆O**zastumotidum #**

zastumotide

19,137,308,342,395-penta[S-(2-amino-2-oxoethyl)]-[[2-aspartic acid(K²>D),3-proline(L³>P)]glycerophosphoryl diester phosphodiesterase (*Haemophilus influenzae* strain 86-028NP EC 3.1.4.46)-(1-127)-peptide fusion protein with [2-aspartic acid(P²>D)]human melanoma-associated antigen 3 (MAGE-3 antigen, antigen MZ2-D, cancer/testis antigen 1.3 or CT1.3) fusion protein with diglycylheptahistidine}

zastumotide

19,137,308,342,395-penta[S-(2-amino-2-oxoéthyl)]-[[2-acide aspartique(K²>D),3-proline(L³>P)]phosphodiesterase du diester de glycérophosphoryle (*Haemophilus influenzae* souche 86-028NP EC 3.1.4.46)-(1-127)-peptide, protéine de fusion avec le [2-acide aspartique(P²>D)]antigène 3 humain associé au mélanome (antigène MAGE-3, antigène MZ2-D, antigen 1.3 associé au cancer des testicules ou CT1.3) protéine de fusion avec la diglycylheptahistidine}


zastumotida

19,137,308,342,395-penta[S-(2-amino-2-oxoetil)]-[[2-ácido aspártico(K²>D),3-prolina(L³>P)]fosfodiesterasa del diéster de glicerofosforilo (*Haemophilus influenzae* cepa 86-028NP EC 3.1.4.46)-(1-127)-péptido, proteína de fusión con el [2-ácido aspártico(P²>D)]antígeno 3 humano asociado al melanoma (antígeno MAGE-3, antígeno MZ2-D, antígeno 1.3 asociado al cáncer de testículos o CT1.3) proteína de fusión con la diglicilheptahistidina}

```
MDPKTLALSL LAAGVLAGCS SHSSNMANTQ MKSDKIIIAH RGASGYLPEH 50
TLESKALAFQ QADYLEQDL AMTKDGRLLV IHDHFLDGLT DVAKKFPFRRH 100
RKDGRYYVID FTLKEIQSLE MTENFETMDL EQRSQHCKPE EGLEARGEAL 150
GLVGAQAPAT EEQEAASSSS TLVEVTLGEV PAAESPDPPO SPQGASSLPT 200
TMNYPLWSQS YEDSSNQEEE GPSTFPDLES EFQAALSRKV AELVHFLLLK 250
YRAREPVTKA EMLGSVVGNW QYFFPVIFSK ASSSLQLVFG IELMEVDPIG 300
HLYIFATCLG LSYDGLLGDN QIMPKAGLLI IVLAI IAREG DCAPEEKIWE 350
ELSVLEVFEQ REDSILGDPK KLLTQHFVQE NYLEYRQVPG SDPACYEFLW 400
GPRALVETSY VKVLHMMVKI SGGPHISYPP LHEWVLREGE EGGHHHHHHH 450
```

Modified residues / Résidus modifiés / Restos modificados

^C
19-137-308-342-395
S-(2-amino-2-oxoethyl)cysteine



Electronic structure available on Mednet: <http://mednet.who.int/>
 # Structure électronique disponible sur Mednet: <http://mednet.who.int/>
 # Estructura electrónica disponible en Mednet: <http://mednet.who.int/>

* http://www.who.int/entity/medicines/services/inn/Radical_Book_2012.pdf

**AMENDMENTS TO PREVIOUS LISTS
MODIFICATIONS APPORTÉES AUX LISTES ANTÉRIEURES
MODIFICACIONES A LAS LISTAS ANTERIORES**

Dénominations communes internationales recommandées (DCI Rec.): Liste 4
(*Chron. Org. mond. Santé, Vol. 16, No. 3, 1962*)

p. 120 **penicillinatum**
pénicilline *remplacer la description par la suivante*
enzyme obtenue par fermentation à partir de cultures de *Bacillus cereus*

Denominaciones Comunes Internacionales Recomendadas (DCI Rec.): Lista 29
(*Información Farmacéutica de la OMS, Vol. 3, No. 3, 1989*)


p. 2 **suprimase** *insertese*
atosiban atosibán

Recommended International Non Proprietary Names (Rec. INN): List 58
Dénominations communes internationales recommandées (DCI Rec.): Liste 58
Denominaciones Comunes Internacionales Recomendadas (DCI Rec.): Lista 58
(*WHO Drug Information, Vol. 21, No. 3, 2007*)

p. 255 **delete/supprimer/suprimase** *insert/insérer/insertese*
methylnaltrexonii bromidum **methylnaltrexoni bromidum**
bromure de méthylnaltrexone *remplacer le nom chimique et la structure par les suivants*
bromuro de metilnaltrexona *sustitúyase el nombre químico y la estructura por los siguientes*

bromure de (17R)-17-(cyclopropylmethyl)-4,5α-époxy-
3,14-dihydroxy-17-méthyl-6-oxomorphinanum

bromuro de (17R)-17-(ciclopropilmetil)-4,5α-epoxi-3,14-dihidroxi-17-metil-
6-oxomorfinanio



Recommended International Non Proprietary Names (Rec. INN): List 66
Dénominations communes internationales recommandées (DCI Rec.): Liste 66
Denominaciones Comunes Internacionales Recomendadas (DCI Rec.): Lista 66
(*WHO Drug Information, Vol. 25, No. 3, 2011*)

p. 307 **egaptivonum pegolum**
egaptivon pegol *replace the structure by the following*
égaptivon pégol *remplacer la structure par la suivante*
egaptivón pegol *sustitúyase la estructura por la siguiente*

(3'-5')-(R-p-Gm-Cm-Gm-Um-dG-dC-dA-Gm-Um-Gm-Cm-Cm-
Um-Um-Cm-Gm-Gm-Cm-dC-Gm-sp-dT-Gm-dC-dG-dG-dT-
Gm-Cm-dC-Um-dC-dC-Gm-Um-dC-Am-Cm-Gm-Cm3'-3'dT)


Legend:

d = 2'-deoxy

m = 2'-O-methyl

-sp- = P-thiophosphate

R-p- =



Recommended International Non Proprietary Names (Rec. INN): List 69
Dénominations communes internationales recommandées (DCI Rec.): Liste 69
Denominaciones Comunes Internacionales Recomendadas (DCI Rec.): Lista 69
(WHO Drug Information, Vol. 27, No. 1, 2013)

p. 42 **actoxumabum #**

actoxumab
actoxumab
actoxumab

replace the description and the structure by the following ones
remplacer la description et la structure par les suivantes
sustitúyase las descripción y la estructura por las siguientes

immunoglobulin G1-kappa, anti-[*Clostridium difficile* toxin A], *Homo sapiens* monoclonal antibody;
 gamma1 heavy chain (1-452) [*Homo sapiens* VH (IGHV3-33*01 (93.90%) -(IGHD)-IGHJ3*02) [8.8.15] (1-122) -IGHG1*03 (CH1 (123-220), hinge (221-235), CH2 (236-345), CH3 (346-450), CHS (451-452)) (123-452)], (225-214')-disulfide with kappa light chain (1'-214') [*Homo sapiens* V-KAPPA (IGKV1-12*01 (98.90%) -IGKJ1*01) [6.3.9] (1'-107') -IGKC*01 (108'-214')]; dimer (231-231'':234-234'')-bisdisulfide

immunoglobuline G1-kappa, anti-[*Clostridium difficile* toxine A], *Homo sapiens* anticorps monoclonal;
 chaîne lourde gamma1 (1-452) [*Homo sapiens* VH (IGHV3-33*01 (93.90%) -(IGHD)-IGHJ3*02) [8.8.15] (1-122) -IGHG1*03 (CH1 (123-220), charnière (221-235), CH2 (236-345), CH3 (346-450), CHS (451-452)) (123-452)], (225-214')-disulfure avec la chaîne légère kappa (1'-214') [*Homo sapiens* V-KAPPA (IGKV1-12*01 (98.90%) -IGKJ1*01) [6.3.9] (1'-107') -IGKC*01 (108'-214')]; dimère (231-231'':234-234'')-bisdisulfure

inmunoglobulina G1-kappa, anti-[*Clostridium difficile* toxina A], anticuerpo monoclonal de *Homo sapiens*;
 cadena pesada gamma1 (1-452) [*Homo sapiens* VH (IGHV3-33*01 (93.90%) -(IGHD)-IGHJ3*02) [8.8.15] (1-122) -IGHG1*03 (CH1 (123-220), bisagra (221-235), CH2 (236-345), CH3 (346-450), CHS (451-452)) (123-452)], (225-214')-disulfuro con la cadena ligera kappa (1'-214') [*Homo sapiens* V-KAPPA (IGKV1-12*01 (98.90%) -IGKJ1*01) [6.3.9] (1'-107') -IGKC*01 (108'-214')]; dímero (231-231'':234-234'')-bisdisulfuro

Heavy chain / Chaîne lourde / Cadena pesada

QVQLVESGGG	VVQPGRSRL	SCAASGFSFS	NYGMHWVRQA	PGKGLEWVAL	50
IWYDGSNEDY	TDSVKGRTI	SRDNSKNTLY	LQMNLSRAED	TAVYYCARWG	100
MVRGVIVDFD	IWGQGTVVTV	SSASTKGPSV	FPLAPSSKST	SGGTAALGCL	150
VKDYFPEPVT	WSWNSGALTS	GVHTFPAVLQ	SSGLYSLSV	VTVPSSSLGT	200
QTYICNVNHK	PSNTKVDKRV	EPKSCDKTHT	CPPCPAPELL	GGPSVFLFPP	250
KPKDTLMISR	TPEVTCVVVD	VSHEDPEVKF	NWYVDGVEVH	NAKTKPREEQ	300
YNSTYRVVSV	LTVLHQDWLN	GKEYCKVSN	KALPAPIEKT	ISKAKGPPE	350
PQVYTLPPSR	EEMTKNQVSL	TCLVKGFPYS	DIAVEWESNG	QPENNYKTTT	400
PVLDSGGSFF	LYSKLTVDKS	RWQQGNVFS	SVMHEALNNH	YTKQSLSLSP	450
GK					452

Light chain / Chaîne légère / Cadena ligera

DIQMTQSPSS	VSASVGDRTV	ITCRASQGIS	SWLAWYQHKP	GKAPKLLIYA	50
ASSLQSGVPS	RFSGSGSGTD	FTLTISLQP	EDFATYYCQ	ANSFFWTFGQ	100
GTKVEIKRTV	AAPSVFIIPP	SDEQLKSGTA	SVVCLNNFY	PREAKVQWKV	150
DNALQSGNSQ	ESVTEQDSKD	STYLSSTLT	LSKADYEKKH	VYACEVTHQG	200
LSPVTKSFN	RGEC				214

Disulfide bridges location / Position des ponts disulfure / Posiciones de los puentes disulfuro

Intra-H (C23-C104)	22-96	149-205	266-326	372-430
	22"-96"	149"-205"	266"-326"	372"-430"
Intra-L (C23-C104)	23'-88'	134'-194'		
	23'"-88'"	134'"-194'"		
Inter-H-L (h 5-CL 126)	225-214'	225"-214'"		
Inter-H-H (h 11, h 14)	231-231"	234-234"		

N-glycosylation sites / Sites de N-glycosylation / Posiciones de N-glicosilación

H CH2 N84.4:
302, 302"

p. 51	crisantasumasum # crisantaspase crisantaspase crisantaspasa	<i>replace the description and the structure by the following ones</i> <i>remplacer la description et la structure par les suivantes</i> <i>sustitúyase la descripción y la estructura por las siguientes</i> L-asparaginase (EC 3.5.1.1, L-asparagine amidohydrolase) <i>Erwinia chrysanthemi</i> (<i>Dickeya dadantii</i>, <i>Pectobacterium chrysanthemi</i>) tetramer α₄ L-asparaginase (EC 3.5.1.1, L-asparagine amidohydrolase) <i>Erwinia chrysanthemi</i> (<i>Dickeya dadantii</i>, <i>Pectobacterium chrysanthemi</i>), tétramère α₄ L-asparaginasa (EC 3.5.1.1, L-asparagina amidohidrolasa) de <i>Erwinia chrysanthemi</i> (<i>Dickeya dadantii</i>, <i>Pectobacterium chrysanthemi</i>), tetrámero α₄ Monomer / Monomère / Monómero <pre>ADKLPNIVIL ATGGTIAGSA ATGTQTTGYK AGALGVDTLI NAVPEVKKLA 50 NVKGEQFSNM ASENMTGDVV LKLSQRVNEL LARDDVDGVV ITHGTDVTEE 100 SAYFLHLTVK SDKPVVEVAA MRPATAISAD GPMNLLEAVR VAGDKQSRGR 150 GVMVVLNDRI GSARYITKTN ASTLDTFKAN EGYLGVIIG NRIYYQNRID 200 KLHTRSVDV VRGLTSLPKV DILYGYQDDP EYLYDAAIQH GVKGIVYAGM 250 GAGSVSVRGI AGMRKAMEKG VVIVRSTRTG NGIVPPDEEL PGLVSDSLNP 300 AHARILLMLA LTRTSDPKVI QEYFHTY 327</pre>
p. 68	nivolumabum # nivolumab nivolumab nivolumab	<i>replace the description by the following</i> <i>remplacer la description par la suivante</i> <i>sustitúyase la descripción por la siguiente</i> immunoglobulin G4-kappa, anti-[<i>Homo sapiens</i> PDCD1 (programmed cell death 1, PD-1, PD1, CD279)], <i>Homo sapiens</i> monoclonal antibody; gamma4 heavy chain (1-440) [<i>Homo sapiens</i> VH (IGHV3-33*01 (91.80%) - (IGHD)-IGHJ4*01) [8.8.6] (1-113) -IGHG4*01 hinge S10>P (221) (114-440)], (127-214')-disulfide with kappa light chain (1'-214') [<i>Homo sapiens</i> V-KAPPA (IGKV3-11*01 (98.90%) -IGKJ1*01) [6.3.9] (1'-107') -IGKC*01 (108'-214')]; (219-219'':222-222'')-bisdisulfide dimer immunoglobuline G4-kappa, anti-[<i>Homo sapiens</i> PDCD1 (protéine 1 de mort cellulaire programmée, PD-1, PD1, CD279)], <i>Homo sapiens</i> anticorps monoclonal; chaîne lourde gamma4 (1-440) [<i>Homo sapiens</i> VH (IGHV3-33*01 (91.80%) - (IGHD)-IGHJ4*01) [8.8.6] (1-113) -IGHG4*01 charnière S10>P (221) (114-440)], (127-214')-disulfure avec la chaîne légère kappa (1'-214') [<i>Homo sapiens</i> V-KAPPA (IGKV3-11*01 (98.90%) -IGKJ1*01) [6.3.9] (1'-107') -IGKC*01 (108'-214')]; dimère (219-219'':222-222'')-bisdisulfure inmunoglobulina G4-kappa, anti-[PDCD1 de <i>Homo sapiens</i> (proteína 1 de muerte celular programada, PD-1, PD1, CD279)], anticuerpo monoclonal de <i>Homo sapiens</i>; cadena pesada gamma4 (1-440) [<i>Homo sapiens</i> VH (IGHV3-33*01 (91.80%) - (IGHD)-IGHJ4*01) [8.8.6] (1-113) -IGHG4*01 bisagra S10>P (221) (114-440)], (127-214')-disulfuro con la cadena ligera kappa (1'-214') [<i>Homo sapiens</i> V-KAPPA (IGKV3-11*01 (98.90%) -IGKJ1*01) [6.3.9] (1'-107') -IGKC*01 (108'-214')]; dímero (219-219'':222-222'')-bisdisulfuro
p. 77-78	rovatirelinun rovatirelin rovatiréline rovatirelina	<i>replace the chemical name by the following</i> <i>remplacer le nom chimique par le suivant</i> <i>sustitúyase el nombre químico por el siguiente</i> (4S,5S)-5-methyl-N-((2S)-1-((2R)-2-methylpyrrolidin-1-yl)-1-oxo-3-(1,3-thiazol-4-yl)propan-2-yl)-2-oxo-1,3-oxazolidine-4-carboxamide

(4S,5S)-5-méthyl-N-[(2S)-1-[(2R)-2-méthylpyrrolidin-1-yl]-1-oxo-3-(1,3-thiazol-4-yl)propan-2-yl]-2-oxo-1,3-oxazolidine-4-carboxamide

(4S,5S)-5-metil-N-[(2S)-1-[(2R)-2-metilpirrolidin-1-il]-1-oxo-3-(1,3-thiazol-4-il)propan-2-il]-2-oxo-1,3-oxazolidina-4-carboxamida

Recommended International Non Proprietary Names (Rec. INN): List 70
Dénominations communes internationales recommandées (DCI Rec.): Liste 70
Denominaciones Comunes Internacionales Recomendadas (DCI Rec.): Lista 70
(WHO Drug Information, Vol. 27, No. 3, 2013)

- p. 291 **filgotinibum**
 filgotinib *replace the chemical name by the following*
 filgotinib *remplacer le nom chimique par le suivant*
 filgotinib *sustitúyase el nombre químico por el siguiente*
- N*-(5-{4-[(1,1-dioxo- λ^6 -thiomorpholin-4-yl)methyl]phenyl}[1,2,4]triazolo[1,5-a]pyridin-2-yl)cyclopropanecarboxamide
- N*-(5-{4-[(1,1-dioxo- λ^6 -thiomorpholin-4-yl)méthyl]phényl}[1,2,4]triazolo[1,5-a]pyridin-2-yl)cyclopropanecarboxamide
- N*-(5-{4-[(1,1-dioxo- λ^6 -tiomorfolin-4-il)metil]fenil}[1,2,4]triazolo[1,5-a]piridin-2-il)ciclopropanocarboxamida
- p. 320 *delete/supprimer/suprimase* *insert/insérer/insertese*
methylnaltrexonii bromidum **methylnaltrexoni bromidum**
 methylnaltrexone bromide *replace the chemical name by the following one*

(17R)-17-(cyclopropylmethyl)-4,5-epoxy-3,14-dihydroxy-17-methyl-6-oxomorphinanum bromide

Recommended International Non Proprietary Names (Rec. INN): List 71
Dénominations communes internationales recommandées (DCI Rec.): Liste 71
Denominaciones Comunes Internacionales Recomendadas (DCI Rec.): Lista 71
(WHO Drug Information, Vol. 28, No. 1, 2014)

- p. 94 **mavatrepum**
 mavatrep *replace the chemical name by the following*
 mavatrep *remplacer le nom chimique par le suivant*
 mavatrep *sustitúyase el nombre químico por el siguiente*
- 2-[2-(2-((1E)-2-[4-(trifluoromethyl)phenyl]ethenyl)-1H-benzimidazol-5-yl)phenyl]propan-2-ol
- 2-[2-(2-((1E)-2-[4-(trifluorométhyl)phényl]éthényl)-1H-benzimidazol-5-yl)phényl]propan-2-ol
- 2-[2-(2-((1E)-2-[4-(trifluorometil)fenil]etenil)-1H-benzoimidazol-5-il)fenil]propan-2-ol
- p. 106 **roniciclibum**
 roniciclib *replace the chemical name by the following*
 roniciclib *remplacer le nom chimique par le suivant*
 roniciclib *sustitúyase el nombre químico por el siguiente*
- (R)-cyclopropyl(4-{[4-[(2R,3R)-3-hydroxybutan-2-yl]oxy]-5-(trifluoromethyl)pyrimidin-2-yl]amino}phenyl)imino- λ^6 -sulfanone

(R)-cyclopropyl(4-[[4-[[[(2R,3R)-3-hydroxybutan-2-yl]oxy]-5-(trifluorométhyl)pyrimidin-2-yl]amino]phényl]imino- λ^6 -sulfanone

(R)-ciclopopil(4-[[4-[[[(2R,3R)-3-hidroxiбутан-2-il]oxi]-5-(trifluorometil)pirimidin-2-il]amino]fenil]imino- λ^6 -sulfanona

p. 111

topsalsynum #

topsalsyn
topsalsyne
topsalsina

replace the description by the following
remplacer la description par la suivante
sustitúyase la descripción por la siguiente

recombinant DNA derived proaerolysin, pore-forming protein, from *Aeromonas hydrophila*, with the furin site substituted with a prostate specific antigen (PSA) cleavage site, fusion protein with 6 histidines, produced in *Escherichia coli* (nonglycosylated):
[427-L-histidine(K>H),428-L-serine(V>S),429-L-serine(R>S),430-L-lysine(R>K),431-L-leucine(A>L),432-L-glutamine(R>Q)]proaerolysin *Aeromonas hydrophila* fusion protein with hexa-L-histidine

proaérolisine, protéine formant des pores, d'*Aeromonas hydrophila* dont le site furine est substitué par le site de clivage reconnu par l'antigène prostatique spécifique (APS), protéine de fusion avec 6 histidines, produite par *Escherichia coli* à partir d'ADN recombinant (non glycosylée) :
[427-L-histidine(K>H),428-L-sérine(V>S),429-L-sérine(R>S),430-L-lysine(R>K),431-L-leucine(A>L),432-L-glutamine(R>Q)]proaérolisine d'*Aeromonas hydrophila* protéine de fusion avec l'hexa-L-histidine

proaerolisina, proteína formadora de poros, d'*Aeromonas hydrophila* cuyo sitio furina está substituido por el sitio de clivaje reconocido por el antígeno prostático específico, proteína de fusión con 6 histidinas, producida por *Escherichia coli* a partir de ADN recombinante (no glicosilada) :
[427-L-histidina(K>H),428-L-serina(V>S),429-L-serina (R>S),430-L-lisina(R>K),431-L-leucina(A>L),432-L-glutamina(R>Q)]proaerolisina d'*Aeromonas hydrophila* proteína de fusión con hexa-L-histidina

Procedure and Guiding Principles / Procédure et Directives / Procedimientos y principios generales

The text of the *Procedures for the Selection of Recommended International Nonproprietary Names for Pharmaceutical Substances* and *General Principles for Guidance in Devising International Nonproprietary Names for Pharmaceutical Substances* will be reproduced in proposed INN lists only.

Les textes de la *Procédure à suivre en vue du choix de dénominations communes internationales recommandées pour les substances pharmaceutiques* et des *Directives générales pour la formation de dénominations communes internationales applicables aux substances pharmaceutiques* seront publiés seulement dans les listes des DCI proposées.

El texto de los *Procedimientos de selección de denominaciones comunes internacionales recomendadas para las sustancias farmacéuticas* y de los *Principios generales de orientación para formar denominaciones comunes internacionales para sustancias farmacéuticas* aparece solamente en las listas de DCI propuestas.